JP5841361B2 - Tricyclic compound and pharmaceutical composition containing the same - Google Patents

Description

The present invention relates to tricyclic compounds and to pharmaceutical compositions containing the tricyclic compounds, and in particular to pharmaceutical compositions for the prevention and treatment of occlusive arterial disease and related prostaglandin mediated disorders.

Atherosclerosis is a disease that underlies some of the lethal diseases of mankind (eg, myocardial infarction and peripheral arterial occlusive disease). Peripheral artery occlusive disease is characterized by atherosclerosis of the extremities and middle arteries, particularly the lower extremities aorta, and lesions are also found in the aorta and iliac arteries. In addition, patients with peripheral arterial occlusive disease often have coronary artery disease and cerebrovascular disease, and are reported to increase the risk of other vascular events such as myocardial infarction and stroke (non-patented). Reference 1). Recently, human genetic studies have reported that DNA variants of the PTGER3 gene encoding prostaglandin E ₂ receptor subtype 3 (EP3) increase the risk of patients with peripheral arterial occlusive disease (Patent Document 1). Therefore, a prostaglandin E ₂ receptor antagonist that binds to the EP3 receptor may be an effective therapeutic or prophylactic agent for peripheral arterial occlusive disease.
Prostaglandin E ₂ is a G- protein coupled receptors EP1, EP2, preferentially binds to EP3 and EP4 receptors. Prostaglandin E ₂ binding to EP3 receptor regulation of ion transport, smooth muscle contraction of the gastrointestinal tract, acid secretion, uterine contraction in fertilization and implantation, been found to play an important role in heating and hypersensitivity ing. EP3 receptor is expressed in many organs such as kidney, gastrointestinal tract, uterus, brain and the like. In the cardiovascular system, it has been reported that EP3 is expressed in vascular endothelial cells and smooth muscle, and at least four EP3 isoforms are expressed in human platelets (Non-patent Document 2).

Prostanoids act through specific membrane receptors belonging to the superfamily of G-protein coupled receptors, but have an essential role in vascular homeostasis including regulation of platelet function. Of the prostanoids, thromboxane A ₂ is a potent platelet aggregation stimulator, while prostaglandin I ₂ inhibits its activation. In contrast, prostaglandin E ₂ has been reported to have a biphasic effect on platelet response, in which platelet aggregation is enhanced at low concentrations and inhibited at high concentrations. The stimulatory effect of prostaglandin E ₂ on platelet aggregation is primarily, been shown to be exerted through the EP3 receptor of the four receptor subtypes are activated by prostaglandin E ₂ Yes.
It has been reported that vascular smooth muscle cells express EP3 receptors within atheromatous plaques, and prostaglandin E ₂ promotes proliferation and migration of vascular smooth muscle cells, an indicator of atheromatous plaques (Non-Patent Document 3). Therefore, chronically produce prostaglandin E ₂ in the blood vessels inflamed sufficient amount, is to activate EP3 receptors in vascular smooth muscle cells and platelets. Locally produced prostaglandin E ₂ enhances platelet aggregation by protein kinase C priming with a lower amount of blood coagulant that itself does not aggregate. Activation of EP3 receptor interferes with the effect of prostaglandin I ₂ and enhances the effect of primary aggregation factor to promote platelet aggregation. Thus, activation of EP3 receptors contributes to the pathology of atherosclerosis and increases the risk of thrombosis observed in the pathology of vasculitis and peripheral arterial occlusive disease.

Current treatments for peripheral arterial occlusive disease are all aimed at reducing the risk of cardiovascular events (eg, myocardial infarction and stroke) by affecting platelet function or reducing the symptoms of lameness. All these treatments affect platelet function. Low doses of aspirin and platelet adenosine diphosphate receptor inhibitors are used for treatments that reduce the risk of cardiovascular events. Binding of adenosine diphosphate to the platelet adenosine diphosphate receptor causes a decrease in platelet cAMP, resulting in platelet activation and aggregation. To reduce symptoms from lameness, platelet phosphodiesterase type 3 inhibitors such as cilostazol that increase intracellular cAMP levels are used. Platelet adenosine diphosphate receptor inhibitors or platelet phosphodiesterase type 3 inhibitors act directly or indirectly to increase the cAMP content of platelets, thereby causing platelet activation and resulting aggregation with thrombus formation Inhibits. EP3 receptor antagonists reduce cAMP. Therefore, by EP3 receptor antagonist to interfere with prostaglandin E ₂ dependent cAMP reduction required to cause aggregation caused platelet activation and consequent or prostaglandins required migration to stimulate Gin by interfering with the E ₂ dependent vascular smooth muscle cells cAMP reduction can be expected to provide therapeutic benefit in peripheral arterial occlusive disease. Furthermore, EP3 receptor antagonists can alleviate the disease by inhibiting or reducing atherosclerotic plaque formation.
To date, many compounds having EP3 receptor antagonistic activity have been reported. For example, an aminothiadiazole derivative represented by the following formula (VI) (Non-Patent Document 4), an N-acylsulfonamide derivative represented by Formula (VII) (Non-Patent Document 5), an indole derivative represented by Formula (VIII) (Non-patent document 6) and indole derivatives represented by formula (IX) (non-patent document 7) and the like. These compounds have an EP3 receptor antagonistic action, but their antiplatelet aggregation action is not sufficient.

US Application Publication 2003/0157599

Lancet, 258, 1257-1264, 2001 British Journal of Haematology, 102, 1204-1211, 1998 Eur. J. Pharmacol. 444, 31-37, 2002 Bioorg. Med. Chem. Lett., 19, 4292-4295, 2009 Bioorg. Med. Chem. Lett., 20, 2639-2643, 2010 J. Med. Chem., 53, 18-36, 2010 Bioorg. Med. Chem. Lett., 19, 6797-6800, 2009

An object of the present invention is to provide a compound having an excellent EP3 receptor antagonistic action and an excellent antiplatelet aggregation action, and further, a pharmaceutical composition containing this compound, particularly occlusive arterial disease and related An object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of prostaglandin-mediated disorders.

As a result of intensive studies, the present inventor has found that the tricyclic compound represented by the general formula (I) has an excellent EP3 receptor antagonistic action, and has completed the present invention.
That is, the present invention is a tricyclic compound represented by the following general formula (I).

[Wherein R ¹ and R ² are a hydrogen atom, an optionally substituted monocyclic or bicyclic aromatic ring, an optionally substituted monocyclic or bicyclic heterocyclic ring, branched A lower alkyl group which may form a ring, a lower alkyl group to which a monocyclic or bicyclic aromatic ring or heterocyclic ring which may have a substituent is bonded, a lower alkoxy group A lower alkyl group having an allyloxy group which may have a substituent, a lower alkyl group having a lower haloalkyloxy group, a lower alkyl group having an amino group which may have a substituent, lower alkylthio Lower alkyl group having a group, lower alkyl group having a lower alkylsulfonyl group, lower alkyl group having a carboxyl group, lower alkyl group having a lower alkoxycarbonyl group, lower alkyl group having a sulfonamide group Group, lower alkyl group having hydroxyl group, lower alkyl group having sulfonic acid, lower alkyl group having cyano group, lower alkyl group having nitro group, lower haloalkyl group, lower alkoxy group (1-5 carbon atoms), lower Haloalkoxy group (1-5 carbon atoms), lower alkoxycarbonyl group (1-5 carbon atoms), halogen atom, hydroxyl group, cyano group, carboxyl group, nitro group, optionally substituted amino group, carbamoyl group, aminosulfonyl Group, lower alkanoyl group (1-5 carbon atoms), optionally substituted allylcarbonyl group, lower alkoxycarbonyl group (1-5 carbon atoms), lower alkylthio group (1-5 carbon atoms), optionally substituted Allylthio group, lower alkylsulfonyl group (1-5 carbon atoms), optionally substituted allylsulfonyl group, lower alkylsulfonylamino group (1-5 carbon atoms), Good allylsulfonyl amino group by, or show a sulfonic acid group.
R ³ may be a monocyclic or bicyclic aromatic ring which may have a substituent, a monocyclic or bicyclic heterocyclic ring which may have a substituent, or a cyclic ring which may have a substituent Indicates.
R ⁴ represents a monocyclic or bicyclic aromatic ring which may have a substituent, or a monocyclic or bicyclic heterocycle which may have a substituent.
X is —CH ₂ —, a carbon atom having an optionally branched lower alkyl group, an oxygen atom, a carbonyl group, a carbon atom having a ring containing an oxygen atom, a sulfur atom, —SO ₂ —, or a substituent. The nitrogen atom which may have a group is shown.
Y is —CH ₂ CH ₂ — (CH ₂ ) m—, —CR ⁵ ═CR ⁶ — (CH ₂ ) m— (R ⁵ and R ⁶ may be the same or different, and may be a hydrogen atom, a halogen atom, Lower alkyl group), -O-CH _2- (CH ₂ ) m-, (optionally substituted cyclo ring (carbon number 1-5))-(CH ₂ ) m-, ethynylene group, or (Monocyclic or bicyclic aromatic ring which may have a substituent) — (CH ₂ ) m— is shown. m is 0-5.
Z represents a bond, —C (═O) —, —C (═S) —, or —SO ₂ —.
n shows 0-5.
Note that the carbon number of each lower alkyl group is 1-5. ]
Or a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof. The present invention also relates to a pharmaceutical composition for treating or preventing a prostaglandin-mediated disease or pathology comprising a compound represented by the general formula (I) as an active ingredient. Moreover, it is a pharmaceutical composition used for the treatment or prevention of pain, inflammation, atherosclerosis, myocardial infarction, stroke or vascular occlusive disorder, which comprises the compound represented by the general formula (I) as an active ingredient. These pharmaceutical compositions may contain a drug selected from a platelet aggregation inhibitor, an HMG-CoA reductase inhibitor, an antihyperlipidemic agent, and a cyclooxygenase inhibitor.

The compound represented by the general formula (I) of the present invention, its prodrug, its pharmaceutically acceptable salt, its hydrate or its solvate has an excellent EP3 receptor antagonistic action and suppresses platelet aggregation It is useful as an agent and is useful in the treatment or prevention of prostaglandin-mediated diseases or pathologies, or the treatment or prevention of pain, inflammation, atherosclerosis, myocardial infarction, stroke or vascular occlusive disorder.

The tricyclic compound of the present invention represented by the general formula (I) will be described in detail. In the general formula (I), R ¹ and R ² are a hydrogen atom, a monocyclic or bicyclic aromatic ring which may have a substituent (for example, phenyl, fluorophenyl, chlorophenyl, bromophenyl, methylphenyl, Methoxyphenyl, aminophenyl, cyanophenyl, thiomethylphenyl, methylsulfonylphenyl, biphenyl, naphthyl, azulene, etc.) or a monocyclic or bicyclic heterocycle (eg pyridine, thiophene, etc.) Furan, pyrimidine, pyrazine, imidazole, thiazol, quinoline, isoquinoline, benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, etc.), lower alkyl groups that may be branched (eg, methyl, ethyl, propyl) Group, isopropyl group, butyl group, pentyl group, etc. ), An alkyl group that may form a ring (for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclopentenyl group, a cyclohexyl group, a cyclohexenyl group, etc.), a monocyclic ring that may have a substituent Lower alkyl group to which an aromatic or bicyclic aromatic ring or heterocyclic ring is bonded (for example, benzyl group, chlorobenzyl group, dichlorobenzyl group, methylbenzyl group, methoxybenzyl group, biphenylmethyl group, phenylethyl group, phenylpropyl group) , Phenylbutyl group, phenylpentyl group, naphthylmethyl group, azulylmethyl group, pyridylmethyl group, thienylmethyl group, furylmethyl group, pyrimidylmethyl group, pyrazylmethyl group, quinolylmethyl group, isoquinolylmethyl group, etc.), having a lower alkoxy group A lower alkyl group (for example, a methoxymethyl group, Toxiethyl group, methoxypropyl group, methoxybutyl group, methoxypentyl group, ethoxymethyl group, ethoxyethyl group, propyloxymethyl group, propyloxyethyl group, butoxymethyl group, butoxymethyl group, pentyloxymethyl group, pentyloxyethyl, etc. ), A lower alkyl group having allyloxy which may have a substituent (for example, phenyloxymethyl group, phenyloxyethyl group, phenyloxypropyl group, phenyloxybutyl group, phenyloxypentyl group, fluorophenyloxymethyl group, Chlorophenyloxymethyl group), lower alkyl groups having a lower haloalkyloxy group (for example, fluoromethoxymethyl group, difluoromethoxymethyl group, trifluoromethoxymethyl group, trifluoromethoxyethyl) , A trifluoromethoxypropyl group, a trifluoromethoxybutyl group, a 2,2,2-trifluoroethoxymethyl group, etc.), a lower alkyl group having an amino group which may have a substituent (for example, aminomethyl group, amino Ethyl group, aminopropyl group, aminobutyl group, aminopentyl group, methylaminomethyl group, dimethylaminomethyl group, ethylaminomethyl group, diethylaminomethyl group, acetylaminomethyl group, methoxycarbonylaminomethyl group, butoxycarbonylmethanesulfonylamino Methyl group, benzyloxycarbonylaminomethyl group, aminomethyl group, methylaminocarbonylaminomethyl group, etc.), lower alkyl group having lower alkylthio group (for example, methylthiomethyl group, ethylthioethyl group, propylthiomethyl group, butylthiol) Methyl group, methylthiopentyl group, methylthioethyl group, methylthiopropyl group, methylthiobutyl group, methylthiopentyl group, etc.), lower alkyl group having lower alkylsulfonyl group (for example, methylsulfonylmethyl group, ethylsulfonylethyl group, propylsulfonylmethyl) Group, butylsulfonylmethyl group, methylsulfonylpentyl group, methylsulfonylethyl group, methylsulfonylpropyl group, methylsulfonylbutyl group, methylsulfonylpentyl group, etc.), a lower alkyl group having a carboxyl group (for example, carboxymethyl group, carboxyethyl group) Group, carboxypropyl group, carboxybutyl group, carboxypentyl group, etc.), lower alkyl group having lower alkoxycarbonyl group (for example, methoxycarbonylmethyl group, A lower alkyl group having a sulfonamido group (for example, aminosulfonylmethyl group, aminosulfonyl), a xycarbonylethyl group, methoxycarbonylpropyl group, methoxycarbonylbutyl group, methoxycarbonylpentyl group, ethoxycarbonylmethyl group, ethoxycarbonylethyl group, etc. Ethyl group, aminosulfonylpropyl group, aminosulfonylbutyl group, aminosulfonylpentyl group, etc.), lower alkyl group having a hydroxyl group (for example, hydroxymethyl group, hydroxyethyl group, hydroxypropyl group, hydroxybutyl group, hydroxypentyl group, etc.) , A lower alkyl group having a sulfonic acid group (for example, a sulfomethyl group, a sulfoethyl group, a sulfopropyl group, a sulfobutyl group, a sulfopentyl group, etc.), a lower alkyl group having a cyano group (For example, cyanomethyl group, cyanoethyl group, cyanopropyl group, cyanobutyl group, cyanopentyl group, etc.), lower alkyl group having nitro group (for example, nitromethyl group, nitroethyl group, nitropropyl group, nitrobutyl group, nitropentyl group, etc.) Lower haloalkyl groups (for example, fluoromethyl group, difluoromethyl group, trifluoromethyl group, 2,2,2-trifluoroethyl group, chloromethyl group, bromomethyl group, iodomethyl group, etc.), lower alkoxy groups (for example, methoxy Group, ethoxy group, propyloxy group, butoxy group, pentyloxy group, etc.), lower haloalkoxy group (for example, fluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, 2,2,2-trifluoroethoxy group, etc.) A lower alkoxycarbonyl group (eg, methoxy) Sicarbonyl group, ethoxycarbonyl group, propyloxycarbonyl group, butoxycarbonyl group, pentyloxycarbonyl group, etc.), halogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom), hydroxyl group, cyano group, carboxyl group, Nitro group, amino group which may be substituted (for example, amino group, methylamino group, dimethylamino group, ethylamino group, diethylamino group, propylamino group, dipropylamino group, isopropylamino group, diisopropylamino group, acetylamino) Group, methylsulfonylamino group, methoxycarbonylamino group, butoxycarbonylamino group, etc.), carbamoyl group, aminosulfonyl group, lower alkanoyl group (for example, acetyl group, propionyl group, butyroyl group, etc.), allyl carbo which may be substituted Group (for example, benzoyl group, fluorobenzoyl group, chlorobenzoyl group, bromobenzoyl group, methylbenzoyl group, methoxybenzoyl group, biphenylcarbonyl group, naphthylcarbonyl group, azulenecarbonyl group, etc.), lower alkoxycarbonyl group (for example, methoxy A carbonyl group, an ethoxycarbonyl group, a propyloxycarbonyl group, a butoxycarbonyl group, a pentyloxycarbonyl group, etc.), a lower alkylthio group (1-5 carbon atoms), an optionally substituted allylthio group (for example, a phenylthio group, a fluorophenylthio group) Group, chlorophenylthio group, bromophenylthio group, methylphenylthio group, methoxyphenylthio group, biphenylthio group, naphthylthio group, azulenethio group, pyridylthio group, thienylthio group, furylthio group, Ginthio group, pyrazinethio group, quinolylthio group, isoquinolylthio group, etc.), lower alkylsulfonyl group (for example, methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, butylsulfonyl group, pentylsulfonyl group, etc.), allylsulfonyl which may be substituted Groups (for example, phenylsulfonyl group, fluorophenylsulfonyl group, chlorophenylsulfonyl group, bromophenylsulfonyl group, methylphenylsulfonyl group, methoxyphenylsulfonyl group, biphenylsulfonyl group, naphthylsulfonyl group, azulenesulfonyl group, pyridylsulfonyl group, thienylsulfonyl) Group, furylsulfonyl group, pyrimidinesulfonyl group, pyrazinesulfonyl group, quinolylsulfonyl group, isoquinolylsulfonyl group, etc.), lower alkyl group Nylamino group (for example, methylaminosulfonyl group, dimethylaminosulfonyl group, ethylaminosulfonyl group, diethylaminosulfonyl group, propylaminosulfonyl group, butylaminosulfonyl group, pentylaminosulfonyl group, etc.), allylsulfonylamino group which may be substituted (For example, phenylaminosulfonyl group, methylphenylaminosulfonyl group, fluorophenylaminosulfonyl group, chlorophenylaminosulfonyl group, bromophenylaminosulfonyl group, methylphenylaminosulfonyl group, methoxyphenylaminosulfonyl group, biphenylaminosulfonyl group, naphthylamino Sulfonyl group, azuleneaminosulfonyl group, pyridylaminosulfonyl group, thienylaminosulfonyl group, furylaminosulfonyl group , Pyrimidineaminosulfonyl group, pyrazineaminosulfonyl group, quinolylaminosulfonyl group, isoquinolylaminosulfonyl group, etc.), sulfonic acid group and the like.

R ³ represents an optionally substituted monocyclic or bicyclic aromatic ring (for example, phenyl, fluorophenyl, chlorophenyl, methylphenyl, methoxyphenyl, aminophenyl, cyanophenyl, thiomethylphenyl, methylsulfonylphenyl) , Naphthalene, azulene, etc.), optionally substituted monocyclic or bicyclic heterocycles (eg, pyridine, furan, thiophene, imidazole, thiazole, benzofuran, benzothiophene, benzimidazole, benzothiazole, Benzothiazol, quinoline, isoquinoline and the like) or a cyclo ring (eg, cyclopentane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cycloheptane, cycloheptene, cyclooctane, cyclooctene, etc.).

R ⁴ may be a monocyclic or bicyclic aromatic ring which may have a substituent (eg, phenyl, fluorophenyl, chlorophenyl, methylphenyl, methoxyphenyl, aminophenyl, cyanophenyl, thiomethylphenyl, methylsulfonylphenyl, Naphthalene, azulene, etc.), monocyclic or bicyclic heterocycles which may have a substituent (for example, pyridine, furan, thiophene, imidazole, thiazol, benzofuran, benzothiophene, benzimidazole, benzothiazol, Quinoline, isoquinoline, etc.).
X is —CH ₂ —, a carbon atom having a lower alkyl group which may be branched (for example, —CH (CH ₃ ) —,
-C (CH ₃ ) _2- , -CH (CH ₂ CH ₃ )-, -C (CH ₂ CH ₃ ) _2- , -CH (CH ₂ CH ₂ CH ₃ )-, -C (CH ₂ CH ₂ CH ₃ ) _2- and the like, an oxygen atom, a carbonyl group, a carbon atom having a ring containing an oxygen atom (for example, a compound represented by the following formula,

(Wherein o is 0 or 1), a sulfur atom, —SO ₂ —, an optionally substituted nitrogen atom (for example, —NH—, —N (CH ₃ ) —, —N (CH ₂ CH ₃ )-, -N (COCH ₃ )-, -N (COCH ₂ CH ₃ )-, -N (COOCH ₃ )-, -N (COOCH ₂ CH ₃ )-, -N (SO ₂ CH ₃ ) -, -N (SO ₂ CH ₂ CH ₃ )-, -N (CONHCH ₃ )-, -N (CONHCH ₂ CH ₃ )-, -N (Ph)-, -N (CH ₂ Ph)-, -N (COPh)-, -N (COCH ₂ Ph)-, -N (SO ₂ Ph)-, -N (SO ₂ CH ₂ Ph)-, etc.).

Y is a _{bond, -CH 2 CH 2 -, -} CH 2 CH 2 CH 2 -, - CH 2 CH 2 CH 2 CH 2 -, - CH 2 CH 2 CH 2 CH 2 CH 2 -, - CH = CH- , -CF = CH-, -CH = CF-, -CF = CF-, -C (CH ₃ ) = CH-, -CH = C (CH ₃ )-, -C (CH ₃ ) = C (CH ₃ ) -, - C (Ph) = CH -, - CH = C (Ph) -, - C (Ph) = C (Ph) -, - CH = CH 2 CH 2 -, - CH 2 -CH = CH 2 _{-, - CH = CH 2 CH} 2 CH 2 -, - CH = CH 2 CH 2 CH 2 CH 2 -, - O-CH 2 -, - O-CH 2 CH 2 -, - O-CH 2 CH 2 CH _2- , —O—CH ₂ CH ₂ CH ₂ CH ₂ —, —O—CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ —, an ethynylene group, an optionally substituted cyclo ring (for example, cyclopropane, Methylcyclopropane, dimethylcyclopropane, cyclobutane, methylcyclobutane, dimethylcyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cycloheptane, cycloheptene, cyclooctane, cyclooctene, etc.), which may have a substituent Cyclic or bicyclic aromatic rings (eg phenyl, fluoro Phenyl, chlorophenyl, methylphenyl, methoxyphenyl, aminophenyl, cyanophenyl, thiomethylphenyl, methylsulfonylphenyl, naphthalene, azulene, etc.).
Z represents a bond, —C (═O) —, —C (═S) —, or —SO ₂ —.

The term “compound” as used herein includes salts, solvates, co-crystals and inclusion complexes of the compounds. The compound of the present invention contains any stereoisomer, optical isomer, tautomer and any mixture thereof. Further, the compounds of the present invention include all compounds that are metabolized in vivo and converted to the general formula (I) and compounds that are converted into salts, so-called prodrugs. Examples of the group forming the prodrug of the present invention include those described in Prog. Med., 5, 2157, 1985, and those described in Hirokawa Shoten 1990 “Development of Drugs”, Volume 7, Molecular Design, page 163. Group. The term “pharmaceutically acceptable salt” is a compound of the invention that retains the biological effectiveness and properties of the compound of the invention and is not biologically or otherwise inconvenient. Examples of compounds that form addition salts of the compounds of the present invention include those described in WILEY-VCH publication “Handbook of Pharmaceutical Salts”. For example, acid addition salts include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, oxalic acid, It is derived from citric acid, malonic acid, fumaric acid, glutaric acid, adipic acid, maleic acid, tartaric acid, succinic acid, mandelic acid, malic acid, pantothenic acid, glutamic acid, aspartic acid and the like. Base addition salts are lithium hydroxide, potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, aluminum hydroxide, ammonia, ethylamine, diethylamine, triethylamine, isopropylamine, diisopropylamine, dicyclohexylamine, ethanolamine, pyrrolidine, Derived from morpholine, piperidine, pyridine, lutidine, collidine, tris (hydroxymethyl) methylamine, tris (hydroxyethyl) methylamine, lysine, arginine, choline and the like.

Specific examples of the compound represented by the general formula (I) are shown below.
(1) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [4- (2,4-dichlorobenzyl) -7-fluoro-1, 2, 3, 4-tetrahydrocyclopenta [b ] Indol-5-yl] acryloyl} amide
(2) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole -1-yl] acryloyl} amide
(3) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Acryloyl} amide
(4) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-methyl-6, 7, 8, 9-tetrahydro-5H-carbazole -1-yl] acryloyl} amide
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-5, 6, 7, 8, 9, 10-hexa Hydrocyclohepta [b] indol-4-yl] acryloyl} amide
(6) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexa Hydrocycloocta [b] indol-4-yl] acryloyl} amide
(7) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydrocycloocta [ b] Indol-4-yl] acryloyl} amide
(8) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4 , 3-b] Indol-6-yl] acryloyl} amide
(9) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -1,3,4,5-tetrahydropyrano [4,3-b ] Indol-6-yl] acryloyl} amide
(10) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia -9-Azafluoren-8-yl] acryloyl} amide

(11) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6-fluoro-3, 3-dioxo-2, 3, 4, 9 -Tetrahydro-1H-3λ ⁶ -thia-9-azafluoren-8-yl] acryloyl} amide
(12) 5- (2,4-dichlorobenzyl) -6- [(E) -3- (4,5-dichlorothiophene-2-sulfonylamino) -3-oxopropenyl] -8-fluoro-1, 3 , 4, 5-Tetrahydropyrido [4, 3-b] indole-2-carboxylic acid ethyl ester
(13) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6- (1,3-dioxolan-2-yl) -3-fluoro -6, 7, 8, 9-Tetrahydro-5H-carbazol-1-yl] acryloyl} amide
(14) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6-oxo-6, 7, 8, 9-tetrahydro -5H-Carbazol-1-yl] acryloyl} amide
(15) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6-hydroxy-6, 7, 8, 9-tetrahydro -5H-Carbazol-1-yl] acryloyl} amide
(16) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [6-tert-butyl-9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9 -Tetrahydro-5H-carbazol-1-yl] acryloyl} amide
(17) 4,5-Dimethylthiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole -1-yl] acryloyl} amide
(18) Thiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] Acryloyl} amide
(19) N-{(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -4 -Methoxybenzenesulfonamide
(20) Benzo [b] thiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole- 1-yl] acryloyl} amide

(21) 5-Bromo N-{(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl } -2-Methoxybenzenesulfonamide
(22) Benzo [1, 2, 5] thiadiazole-4-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro- 5H-Carbazol-1-yl] acryloyl} amide
(23) Naphthalene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] Acryloyl} amide
(24) (E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] -N- (3-methyl Isoxazol-5-yl) acrylamide
(25) (E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] -N- (3, 4 -Dimethylisoxazol-5-yl) acrylamide
(26) N- (4-Bromo-3-methylisoxazol-5-yl) -3-[9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro -5H-Carbazol-1-yl] acrylamide
(27) (E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] -N- (5-methyl Isoxazol-3-yl) acrylamide
(28) (E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] -N-tert-butoxycarbonyl -2- (Ethylaminosulfonylphenyl) acrylamide
(29) N-{(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acroyl} -4 -Fluorobenzenesulfonamide
(30) N-{(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acroyl} -3 , 4-Difluorobenzenesulfonamide

(31) 5-Bromo N-{(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl } -2-Methoxybenzenesulfonamide (Compound 31)
(32) Benzo [b] thiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] Acryloyl} amide
(33) 5-Bromo N-{(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -2- Methoxybenzenesulfonamide
(34) Benzo [1, 2, 5] thiadiazole-4-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazole- 1-yl] acryloyl} amide
(35) N-{(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -4-fluorobenzenesulfone Amide
(36) N-{(E) -3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -3, 4-difluoro Benzenesulfonamide
(37) 5-Bromo N-{(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indole -6-yl] acryloyl} -2-methoxybenzenesulfonamide
(38) Benzo [1, 2, 5] thiadiazole-4-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyra [4, 3-b] indol-6-yl] acryloyl} -2-methoxybenzenesulfonamide
(39) N-{(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indole-6- Yl] acryloyl} -4-fluorobenzenesulfonamide
(40) N-{(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indole-6- Yl] acryloyl} -3, 4-difluorobenzenesulfonamide

(41) Benzo [1, 2, 5] thiadiazole-4-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -1, 3, 4, 5-tetrahydropyrano [4, 3-b] Indol-6-yl] acryloyl} amide
(42) N-{(E) -3- [5- (2,4-dichlorobenzyl) -1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] acryloyl} -4-Fluorobenzenesulfonamide
(43) N-{(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4,3-b] indole-6- Yl] acryloyl} -3, 4-difluorobenzenesulfonamide
(44) N-{(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole- 4-yl] acryloyl} -4-fluorobenzenesulfonamide
(45) N-{(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole- 4-yl] acryloyl} -3, 4-fluorobenzenesulfonamide
(46) Chlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b ] Indol-6--yl) acryloyl] amide
(47) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (3-fluoro-9-naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Il) acryloyl] amide
(48) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (3-fluoro-9-naphthalen-2-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Il) acryloyl] amide
(49) 4, 5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [b] thiophen-2-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H- Carbazol-1-yl) acryloyl] amide
(50) 4, 5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [b] thiophen-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H- Carbazol-1-yl) acryloyl] amide

(51) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-biphenyl-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Il) acryloyl] amide
(52) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-biphenyl-4-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Il) acryloyl] amide
(53) 4, 5-Dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [1, 2, 5] -thiadiazol-5-ylmethyl-3-fluoro-6, 7, 8, 9 -Tetrahydro-5H-carbazol-1-yl) acryloyl] amide
(54) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- (9- (4-chloro-2-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H -Carbazol-1-yl) acryloyl} amide
(55) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- (9- (2-chloro-4-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H -Carbazol-1-yl) acryloyl} amide
(56) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-cyclohexylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl Amides
(57) 4, 5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl] Amide
(58) 4,5-Dichlorothiophene-2-sulfonic acid {[(E) -9- (3-methylazulen-1-yl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Acryloyl} amide
(59) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [8-fluoro-5-(3-methylazulen-1-yl) -1, 3, 4, 5-tetrahydropyra [4, 3-b] indol-6-yl] acryloyl} amide
(60) 4,5-dichlorothiophene-2-sulfonic acid {3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Propionyl} amide

(61) 4, 5-dichlorothiophene-2-sulfonic acid {3- [9- (2, 4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionyl} amide
(62) 4,5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b ] Indol-6-yl] propionyl} amide
(63) 4,5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] Indol-4-yl] propionyl} amide
(64) 4,5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole -4-yl] propionyl} amide
(65) 4,5-dichlorothiophene-2-sulfonic acid {(E) -4- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole -1-yl] bute-3-enoyl} amide
(66) 4,5-dichlorothiophene-2-sulfonic acid {(E) -4- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4 , 3-b] Indol-6-yl] bute-3-enoyl} amide
(67) 4,5-dichlorothiophene-2-sulfonic acid {4- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Butyryl} amide
(68) 4,5-dichlorothiophene-2-sulfonic acid {2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yloxy ] Acetyl} amide
(69) 4,5-dichlorothiophene-2-sulfonic acid {2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Cyclopropanecarbonyl} amide
(70) 4, 5-dichlorothiophene-2-sulfonic acid {2- [9- (2, 4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarbonyl } Amido

(71) 4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b ] Indol-6-yl] cyclopropanecarbonyl} amide
(72) 4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] Indol-4-yl] cyclopropanecarbonyl} amide
(73) 4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole -4-yl] cyclopropanecarbonyl} amide
(74) 4,5-Dichlorothiophene-2-sulfonic acid {(Z) -2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Cyclopent-1-enecarbonyl} amide
(75) 4,5-dichlorothiophene-2-sulfonic acid {4- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] benzoylamide
(76) N- {3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionyl} -3, 4-difluoro Benzenesulfonamide
(77) N- {2- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarbonyl} -3, 4 -Difluorobenzenesulfonamide
(78) N- {2- [5- (2,4-Dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] cyclopropane Carbonyl} -3, 4-difluorobenzenesulfonamide The compounds of the above (1), (2) --- (78) are cited below as Compound (1), Compound (2) --- Compound (78), respectively. To do.
The compound of the present invention can be produced by the following method. Examples of the protecting group used in the production include protecting groups described in “Protective Groups in Organic Synthesis” published by WILEY-Interscience.
A. A method for producing the compound represented by the general formula (II) (Z = SO ₂ ) is shown in Scheme 1.

(In the formula, A represents a halogen atom, an alkylsulfonyl group, an arylsulfonyl group, a trifluoromethanesulfonyl group, or the like. R ¹ to R ⁴ , X, m, and n are as defined above.)
First step: A step of obtaining phenylhydrazine derivative (XI) from compound (X). The phenylhydrazine derivative (XI) can be produced by a method described in the literature or a method based thereon (for example, Azo and Diazo Chemistry. P169. 1961).
Second step: A step of reacting the phenylhydrazine derivative (XI) with the carbonyl compound (XII) to obtain the indole derivative (XIII). Indole derivatives (XIII) can be prepared by methods described in the literature or by methods based thereon (for example, Org. Synth., IV, 884, 1963 .: Chem. Pharm. Bull., 19 , 256, 1971 .: J. Heterocycl. Chem., 7 , 239, 1970 .: J. Am. Chem. Soc., 77 , 4319, 1955.
Third step: In this step, compound (XIV) is obtained by reacting indole derivative (XIII) with an unsaturated compound (for example, acrylic ester, 3-butenoic acid, etc.). The reaction is carried out using a palladium coordination compound as a catalyst in the presence of a base. Examples of the palladium coordination compound used in this reaction include tetrakis (triphenylphosphine) palladium (0), bis (triphenylphosphine) palladium chloride (2), and palladium acetate-tri-o-tolylphosphine. Bases include sodium hydrogen carbonate, sodium carbonate, potassium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium-t-butoxide, potassium- Examples thereof include t-butoxide, potassium fluoride, cesium fluoride, triethylamine, N, N-diisopropylethylamine, pyridine, lutidine, collidine and the like. The reaction is usually carried out in an inert solvent, and preferable examples include benzene, toluene, xylene, 1,4-dioxane, tetrahydrofuran, chloroform, methanol, N, N-dimethylformamide, N-methylpyrrolidone, dimethylsulfoxide, Examples include acetonitrile, ethyl acetate, diethyl ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, water and the like. The reaction is usually carried out at room temperature to the solvent reflux temperature.

Fourth step: A step of obtaining the compound (XV) by hydrolysis of the compound (XIV). For the reaction, an acid such as hydrochloric acid, nitric acid, sulfuric acid or trifluoroacetic acid or a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, barium hydroxide, sodium carbonate or potassium carbonate is used. The reaction is usually carried out in an inert solvent, and preferable examples include water, methanol, ethanol, tetrahydrofuran, 1,4-dioxane and the like. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.
Step 5: Step of obtaining compound (XVII) by reaction of compound (XV) with alkylating agent (XVI). The reaction is carried out in the presence of a base, which includes lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium-t- Butoxide, potassium-t-butoxide, diisopropyllithium amide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, methyllithium, butyllithium, phenyllithium, lithium hydride, sodium hydride, And potassium hydride, 1,8-diazabicyclo [5.4.0] undec-7-ene, and the like. The reaction is usually carried out in an inert solvent, preferably methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, ethyl acetate, diethyl Examples include ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, benzene, toluene, xylene, dichloromethane, chloroform and the like. The reaction is usually performed at −78 ° C. to the solvent reflux temperature.

Sixth step: Compound (XIX) is obtained by reacting compound (XVII) with sulfonamide derivative (XVIII). The reaction is usually 1,3-dicyclohexylcarbodiimide, diphenylphosphoryl azide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, 1,1'-carbonyldiimidazole, 2-chloro-1-methylpyridinium iodide. -Performed in an inert solvent in the presence of a condensing agent such as dye, O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate Suitable solvents include tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, benzene, toluene, xylene, N, N-dimethylformamide, N-methylpyrrolidone, acetonitrile, ethyl acetate, dimethyl sulfoxide, diethyl ether, t-butyl Examples include methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and acetone. Further, 1-hydroxybenzotriazole or the like may be added. Examples of the base include triethylamine, N, N-diisopropylethylamine, N-methylmorpholine, N-ethylmorpholine, pyridine, lutidine, collidine, 4-dimethylaminopyridine and the like. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.
B. A production method of the compound compound (Z = SO ₂ ) represented by the general formula (III) is shown in Scheme 2.

（式中、Ａは ハロゲン原子、アルキルスルホニル基、アリールスルホニル基又はトリフルオロメタンスルホニル基等を示す。Ｒ¹ からＲ⁴、Ｘ、ｍ及び ｎは、前記と同義である。）
第１工程：前記の化合物（XVII）を水素添加反応して化合物（XX）を得る工程である。反応は触媒存在下で行われ、触媒としてはパラジウム-炭素、水酸化パラジウム、ロジウム-炭素、ルテニウム-炭素、白金-炭素、二酸化白金等が挙げられる。反応は通常、水素ガス、大気圧下或いは加圧下で行われ、反応溶媒としてはメタノール、エタノール、2-プロパノール、テトラヒドロフラン、1, 4-ジオキサン、N, N-ジメチルホルムアミド、N-メチルピロリドン、アセトニトリル、酢酸エチル、ジエチルエーテル、t-ブチルメチルエーテル、シクロペンチルメチルエーテル、1, 2-ジメトキシエタン、ベンゼン、トルエン、キシレン等が挙げられる。また、塩酸、硝酸、硫酸、酢酸等の酸を添加してもよい。反応は、通常、0 ℃から溶媒還流温度で行われる。
第２工程：化合物（XX）とスルホンアミド誘導体（XVII）との反応より化合物（XXI）を得る工程である。反応は通常、1, 3-ジシクロへキシルカルボジイミド、ジフェニルホスホリルアジド、1-(3-ジメチルアミノプロピル)-3-エチルカルボジイミド、1,1’-カルボニルジイミダゾール、2-クロロ-1-メチルピリジ二ウムヨ−ダイド、O-(7-アザベンゾトリアゾール-1-イル)-N, N,N’,N’-テトラメチルウロニウムヘキサフルオロホスフェート等の縮合剤存在下、不活性溶媒中で行われ、好適な溶媒としてはテトラヒドロフラン、1, 4-ジオキサン、アセトニトリル、ジクロロメタン、クロロホルム、ベンゼン、トルエン、キシレン、N, N-ジメチルホルムアミド、N-メチルピロリドン、アセトニトリル、酢酸エチル、ジメチルスルホキシド、ジエチルエーテル、t-ブチルメチルエーテル、シクロペンチルメチルエーテル、1, 2-ジメトキシエタン、アセトン等が挙げられる。また、1-ヒドロキシベンゾトリアゾール等を添加してもよい。塩基としては、トリエチルアミン、N, N-ジイソプロピルエチルアミン、N-メチルモルホリン、N-エチルモルホリン、ピリジン、ルチジン、コリジン、4-ジメチルアミノピリジン等が挙げられる。反応は通常、0℃から溶媒還流温度で行われる。
Ｃ．一般式（IV）で示される化合物（Z= SO₂）の製造方法をスキーム３に示す。

(In the formula, A represents a halogen atom, an alkylsulfonyl group, an arylsulfonyl group, a trifluoromethanesulfonyl group, or the like. R ¹ to R ⁴ , X, m, and n are as defined above.)
First step: This is a step of obtaining a compound (XX) by hydrogenation reaction of the compound (XVII). The reaction is carried out in the presence of a catalyst, and examples of the catalyst include palladium-carbon, palladium hydroxide, rhodium-carbon, ruthenium-carbon, platinum-carbon, platinum dioxide and the like. The reaction is usually carried out under hydrogen gas, atmospheric pressure or pressure, and the reaction solvent is methanol, ethanol, 2-propanol, tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide, N-methylpyrrolidone, acetonitrile. Ethyl acetate, diethyl ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, benzene, toluene, xylene and the like. In addition, an acid such as hydrochloric acid, nitric acid, sulfuric acid, or acetic acid may be added. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.
Second step: In this step, compound (XXI) is obtained by reacting compound (XX) with sulfonamide derivative (XVII). The reaction is usually 1,3-dicyclohexylcarbodiimide, diphenylphosphoryl azide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, 1,1'-carbonyldiimidazole, 2-chloro-1-methylpyridinium iodide. -Performed in an inert solvent in the presence of a condensing agent such as dye, O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate Suitable solvents include tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, benzene, toluene, xylene, N, N-dimethylformamide, N-methylpyrrolidone, acetonitrile, ethyl acetate, dimethyl sulfoxide, diethyl ether, t-butyl Examples include methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and acetone. Further, 1-hydroxybenzotriazole or the like may be added. Examples of the base include triethylamine, N, N-diisopropylethylamine, N-methylmorpholine, N-ethylmorpholine, pyridine, lutidine, collidine, 4-dimethylaminopyridine and the like. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.
C. A production method of the compound represented by the general formula (IV) (Z = SO ₂ ) is shown in Scheme 3.

(In the formula, A represents a halogen atom, an alkylsulfonyl group, an arylsulfonyl group, a trifluoromethanesulfonyl group, or the like. R ¹ to R ⁴ , X, m, and n are as defined above.)
1st process: It is a process of obtaining a compound (XXII) from reaction of the said compound (XIV) and an alkylating agent (XVI). The reaction is carried out in the presence of a base, which includes lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium-t- Butoxide, potassium-t-butoxide, diisopropyllithium amide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, methyllithium, butyllithium, phenyllithium, lithium hydride, sodium hydride, Examples include potassium hydride, 1,8-diazabicyclo [5.4.0] undec-7-ene, and the like. The reaction is usually carried out in an inert solvent, preferably methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, ethyl acetate, diethyl Examples include ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, benzene, toluene, xylene dichloromethane, chloroform, and the like. The reaction is usually performed at −78 ° C. to the solvent reflux temperature.

Second step: A step of obtaining the compound (XXIII) from the cyclopropanation reaction of the compound (XXII). The reaction uses trimethylsulfonium iodide and a base, and the base is sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium-t-butoxide, potassium-t-butoxide, diisopropyllithium. Examples include amide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, methyllithium, butyllithium, phenyllithium, lithium hydride, sodium hydride, and potassium hydride. The reaction is usually carried out in an inert solvent, and preferred ones are tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, diethyl ether, t-butyl methyl ether, cyclopentyl. Examples include methyl ether, 1,2-dimethoxyethane, benzene, toluene, xylene and the like. The reaction is usually performed at −78 ° C. to the solvent reflux temperature.
Third step: A step of obtaining the compound (XXIV) by hydrolysis of the compound (XXIII). For the reaction, an acid such as hydrochloric acid, nitric acid, sulfuric acid or trifluoroacetic acid or a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide or barium hydroxide is used. The reaction is usually carried out in an inert solvent, and preferable examples include water, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.

Fourth step: In this step, compound (XXV) is obtained by reacting compound (XXIV) with sulfonamide derivative (XVIII). The reaction is usually 1,3-dicyclohexylcarbodiimide, diphenylphosphoryl azide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, 1,1'-carbonyldiimidazole, 2-chloro-1-methylpyridinium iodide. -Performed in an inert solvent in the presence of a condensing agent such as dye, O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate Suitable solvents include tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, benzene, toluene, xylene, N, N-dimethylformamide, N-methylpyrrolidone, acetonitrile, ethyl acetate, dimethyl sulfoxide, diethyl ether, t-butyl Examples include methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and acetone. Further, 1-hydroxybenzotriazole or the like may be added. Examples of the base include triethylamine, N, N-diisopropylethylamine, N-methylmorpholine, N-ethylmorpholine, pyridine, lutidine, collidine, 4-dimethylaminopyridine and the like. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.
D. A production method of the compound represented by the general formula (V) (Z = SO ₂ ) is shown in Scheme 4.

(In the formula, A represents a halogen atom, an alkylsulfonyl group, an arylsulfonyl group, a trifluoromethanesulfonyl group, or the like. R ¹ to R ⁴ , X, m, and n are as defined above.)
1st process: It is a process of obtaining a compound (XXVI) from reaction of the said compound (XIII) and an alkylating agent (XVI). The reaction is carried out in the presence of a base, which includes lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium-t- Butoxide, potassium-t-butoxide, diisopropyllithium amide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, methyllithium, butyllithium, phenyllithium, lithium hydride, sodium hydride, Examples include potassium hydride, 1,8-diazabicyclo [5.4.0] undec-7-ene, and the like. The reaction is usually carried out in an inert solvent, preferably methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, ethyl acetate, diethyl Examples include ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, benzene, toluene, xylene dichloromethane, chloroform, and the like. The reaction is usually performed at −78 ° C. to solvent reflux temperature.
Second step: A step of obtaining the compound (XXVII) from the compound (XXVI). Compound (XXVI) was reacted with diisopropyllithium amide, lithium hexamethyldisilazide, methyllithium, butyllithium, phenyllithium, etc. to form a lithium reagent, followed by treatment with trimethylborate or triisopropylborate. Compound (XXVII) is produced by acid hydrolysis of a boronic ester. The reaction is usually carried out in an inert solvent, and preferred ones are tetrahydrofuran, 1,4-dioxane, diethyl ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, benzene, toluene, xylene. Etc. The reaction is usually performed at −78 ° C. to the solvent reflux temperature. Examples of the acid used for hydrolysis of the boronic acid ester include hydrochloric acid, nitric acid, sulfuric acid and the like.

Third step: Step of obtaining compound (XXVIII) by oxidation reaction of compound (XXVII). As the oxidizing agent, hydrogen peroxide, m-chloroperbenzoic acid, or the like can be used. The reaction is usually carried out in an inert solvent, and preferred ones are tetrahydrofuran, 1,4-dioxane, diethyl ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, dichloromethane, chloroform, water. And acetic acid. The reaction is usually performed at −78 ° C. to the solvent reflux temperature.
Fourth step: In this step, compound (XXX) is obtained by reacting compound (XXVIII) with alkylating agent (XXIX). The reaction is carried out in the presence of a base, which includes lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium-t- Butoxide, potassium-t-butoxide, diisopropyllithium amide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, methyllithium, butyllithium, phenyllithium, lithium hydride, sodium hydride, Examples include potassium hydride, 1,8-diazabicyclo [5.4.0] undec-7-ene, and the like. The reaction is usually carried out in an inert solvent, preferably methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, ethyl acetate, diethyl Examples include ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, benzene, toluene, xylene, dichloromethane, chloroform and the like. The reaction is usually performed at −78 ° C. to the solvent reflux temperature.
Step 5: Step of obtaining compound (XXXI) by hydrolysis of compound (XXX). For the reaction, an acid such as hydrochloric acid, nitric acid, sulfuric acid or trifluoroacetic acid or a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide or barium hydroxide is used. The reaction is usually carried out in an inert solvent, and preferable examples include water, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.

Step 6: Step for obtaining compound (XXXII) by reaction of compound (XXXI) with sulfonamide derivative (XVIII). The reaction is usually 1,3-dicyclohexylcarbodiimide, diphenylphosphoryl azide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, 1,1′-carbonyldiimidazole, 2-chloro-1-methylpyridinium iodide. -Performed in an inert solvent in the presence of a condensing agent such as dye, O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate Suitable solvents include tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, benzene, toluene, xylene, N, N-dimethylformamide, N-methylpyrrolidone, acetonitrile, ethyl acetate, dimethyl sulfoxide, diethyl ether, t-butyl. Examples include methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, and acetone. . Further, 1-hydroxybenzotriazole or the like may be added. Examples of the base include triethylamine, N, N-diisopropylethylamine, N-methylmorpholine, N-ethylmorpholine, pyridine, lutidine, collidine, 4-dimethylaminopyridine and the like. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.
E. A method for producing the compound represented by the general formula (I) (Y = cyclopentene, Z = SO ₂ ) is shown in Scheme 5.

(Wherein R ¹ to R ⁴ , X, m and n are as defined above.)
First step: A step of obtaining compound (XXXIV) by reaction of boronic acid derivative (XXVII) and enol triflate (XXXIII). The reaction is carried out using a palladium coordination compound as a catalyst in the presence of a base. Examples of the palladium coordination compound used in this reaction include tetrakis (triphenylphosphine) palladium (0), bis (triphenylphosphine) palladium chloride (2), and palladium acetate-tri-o-tolylphosphine. Bases include sodium hydrogen carbonate, sodium carbonate, potassium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium-t-butoxide, potassium- Examples thereof include t-butoxide, potassium fluoride, cesium fluoride, triethylamine, N, N-diisopropylethylamine, pyridine and the like. The reaction is usually carried out in an inert solvent, and preferable examples include benzene, toluene, 1,4-dioxane, tetrahydrofuran, chloroform, methanol, N, N-dimethylformamide, N-methylpyrrolidone, acetonitrile, ethyl acetate, Examples include diethyl ether, t-butyl methyl ether, cyclopentyl methyl ether, 1,2-dimethoxyethane, benzene, toluene, xylene, water and the like. The reaction is usually carried out at room temperature to the solvent reflux temperature.
Second step: A step of obtaining compound (XXXV) by hydrolysis of compound (XXXIV). For the reaction, an acid such as hydrochloric acid, nitric acid, sulfuric acid or trifluoroacetic acid or a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, barium hydroxide, sodium carbonate or potassium carbonate is used. The reaction is usually carried out in an inert solvent, and preferable examples include water, methanol, ethanol, tetrahydrofuran, 1,4-dioxane and the like. The reaction is usually performed at 0 ° C. to the solvent reflux temperature.

Third step: Compound (XXXVI) is obtained by reacting compound (XXXV) with sulfonamide derivative (XVIII). The reaction is usually 1,3-dicyclohexylcarbodiimide, diphenylphosphoryl azide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, 1,1'-carbonyldiimidazole, 2-chloro-1-methylpyridinium iodide. Id, O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate Solvents include tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, benzene, toluene, xylene, N, N-dimethylformamide, N-methylpyrrolidone, acetonitrile, ethyl acetate, dimethyl sulfoxide, diethyl ether, t-butylmethyl Examples include ether, cyclopentyl methyl ether, and acetone. Further, 1-hydroxybenzotriazole or the like may be added. Examples of the base include triethylamine, N, N-diisopropylethylamine, N-methylmorpholine, N-ethylmorpholine, pyridine, lutidine, collidine, 4-dimethylaminopyridine and the like. The reaction is usually performed at 0 ° C. to solvent reflux temperature.

The reaction product obtained by each of the above production methods is isolated as a free salt or as an addition salt and purified. The salt can be produced by subjecting it to a normal salt formation reaction. Isolation and purification are performed by applying chemical operations such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various chromatography.

The compound represented by the general formula (I) of the present invention, its prodrug, its pharmaceutically acceptable salt, its hydrate or its solvate has an excellent EP3 receptor antagonistic action and inhibits platelet aggregation It is useful as an agent and is useful in the treatment or prevention of prostaglandin-mediated diseases or pathologies, specifically pain, inflammation, atherosclerosis, myocardial infarction, stroke or vaso-occlusive disorders. In addition, an agent selected from a platelet aggregation inhibitor, an HMG-CoA reductase inhibitor, an antihyperlipidemic agent and a cyclooxygenase inhibitor may be added to a pharmaceutical composition containing this as an active ingredient. The combined use of these high cholesterol therapeutic agent, neutral fat therapeutic agent and antithrombotic agent is highly effective in suppressing atherosclerosis and the accompanying thrombus formation.

When the compound represented by the general formula (I) is used as the above-mentioned pharmaceutical, an appropriate pharmacologically acceptable carrier, excipient (for example, starch, lactose, sucrose, calcium carbonate, calcium phosphate, etc.), binder (Eg, starch, gum arabic, carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, alginic acid, gelatin, polyvinylpyridone, etc.), lubricant (eg, stearic acid, magnesium stearate, calcium stearate, talc, etc.), disintegrant ( For example, it is mixed with carboxymethyl cellulose, talc, etc.), diluent (for example, physiological saline, etc.) and the like orally or in the form of powders, fine granules, capsules, tablets, external preparations or injections etc. It can be administered parenterally. The dose of the compound of the present invention varies depending on the administration route, the target disease, the symptom of the patient, the body weight or age, and the compound used, and can be appropriately set according to the purpose of administration. In general, when administered orally to an adult, 0.01 to 1000 mg / kg body weight / day, preferably 0.05 to 500 mg / kg body weight / day, is preferably administered in one to several times a day.

[Evaluation of inhibition of platelet aggregation]
Blood was collected from the abdominal aorta of a rat anesthetized with ether using a syringe containing 3.8% sodium citrate. Platelet rich plasma (PRP) was obtained by centrifugation at 150 xg. The remaining blood was centrifuged again at 2,400 xg for 10 minutes to obtain platelet poor (PPP). Platelet counts were counted with a hemocytometer (Model PC-608, ELMA) and diluted to the desired platelet concentration (400,000-600,000 platelets / μL) using PPP.
Platelet aggregation was measured with a platelet aggregation capacity measuring device (Model PAM-8T, ELMA). Collagen (LMS) and sulprostone (Cayman Chemicals) were used as platelet aggregation promoters. To a cuvette containing 215 μL of PRP, 10 μL of each compound solution of the compound Nos. 63, 69, 71, 73 and the compound represented by the general formula (VIII) (compound VIII) was added, and sulprostone was added after 2 minutes. 10 μL of solution (final concentration 100 nM) was added, and 15 μL of collagen suspension (final concentration 0.3 to 0.4 mg / mL) was further added 2 minutes later. A curve of aggregation for 7 minutes was recorded from the addition of the collagen suspension. The test compound concentration (IC ₅₀ value) required to inhibit platelet aggregation by 50% was calculated. The results are shown in Table 1.
Prostaglandin receptors include four types of receptors, EP1, EP2, EP3, and EP, but platelets express only EP3. Sulprostone binds to the prostaglandin receptor and exerts an action. Since platelets are used in this experiment, it is judged that the platelet aggregation inhibitory effect is exerted through the antagonistic action against the EP3 receptor of the prostaglandin receptors. Therefore, it can be seen from Table 1 that the compounds of Compound Nos. 63, 69, 71 and 73 have an EP3 receptor antagonistic action superior to that of Compound VIII and exhibit a strong platelet aggregation inhibitory action.

The invention is further illustrated in the following examples. These examples do not limit the invention and may vary within the scope of the invention. Proton nuclear magnetic resonance spectrum ( ¹ H-NMR) The following abbreviations were used for data description. That is, s is a singlet, d is a doublet, t is a triplet, q is a quartet, m is a multiplet, and b is broad.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [4- (2,4-dichlorobenzyl) -7-fluoro-1, 2, 3, 4-tetrahydrocyclopenta [b] indole- Production example of 5-yl] acryloyl} amide (compound 1)
(1) Production of (2-bromo-4-fluorophenyl) hydrazine hydrochloride
To a mixture of 6.2 mL of 2-bromo-4-fluoroaniline acetic acid (6.2 mL) and concentrated hydrochloric acid (18.6 mL) was added dropwise a solution of sodium nitrite (4.412 g) in water (8.2 mL) at 0 ° C. or lower, and the mixture was stirred at the same temperature for 1 hour. The reaction solution was poured into a mixture of sodium sulfite 36.600 g of water 123.7 mL, and the mixture was stirred at 60-70 ° C. for 1.5 hours. The reaction solution was cooled to room temperature, poured into 61.8 mL of concentrated hydrochloric acid, and the mixture was stirred at 60-80 ° C. for about 12.5 hours. After cooling the reaction solution to room temperature, insolubles were collected by filtration. The insoluble material was washed with water and dried to give 13.049 g of the title compound.
(2) Preparation of 5-bromo-7-fluoro-1, 2, 3, 4-tetrahydrocyclopenta [b] indole (2-bromo-4-fluorophenyl) hydrazine hydrochloride 5.000 g, 10% aqueous sodium hydroxide A mixture of 13.0 mL and chloroform 20.0 mL was stirred at room temperature. The chloroform layer was separated, washed with water, and dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure to obtain (2-bromo-4-fluorophenyl) hydrazine. To a solution of (2-bromo-4-fluorophenyl) hydrazine in 18.0 mL of benzene, 0.739 g of cyclopentanone was added at room temperature and stirred for 1 hour, and then anhydrous sodium sulfate was added. After filtration, 1.197 g of zinc chloride was added to the filtrate at room temperature, and then heated to reflux for 22 hours. After the reaction solution was cooled to room temperature, a 10% aqueous sodium hydroxide solution was added. The organic layer was separated, washed successively with water and saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was evaporated under reduced pressure, and 1.276 g of the title compound was separated from the obtained residue by silica gel column chromatography.
¹ H-NMR (CDCl ₃ ) δ = 2.50-2.57 (m, 2H), 2.76-2.78 (m, 2H), 2.86-2.90 (m, 2H), 7.01-7.05 (m, 2H), 7.99 (bs, 1H).

(3) Preparation of (E) -3- (7-fluoro-1, 2, 3, 4-tetrahydrocyclopenta [b] indol-5-yl) acrylic acid methyl ester
5-Bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta [b] indole 1.200 g of acetonitrile in 12.0 mL solution of triethylamine 4.0 mL, acrylic acid methyl ester 0.85 mL, tri- (o-tolyl) phosphine After adding 0.216 g and palladium acetate (II) 0.053 g at room temperature, the mixture was heated to reflux for 19 hours. The reaction mixture was cooled to room temperature, saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was evaporated under reduced pressure, and 1.087 g of the title compound was separated from the resulting residue by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (DMSO-d ₆ ) δ = 2.44−2.51 (m, 2H), 2.72 (t, J = 7 Hz, 2H), 2.84 (t, J = 7 Hz, 2H), 3.76 (s, 3H), 6.75 (d, J = 16Hz, 1H), 7.17 (dd, J = 2Hz, 10Hz, 1H), 7.35 (dd, J = 2Hz, 10Hz, 1H), 8.12 (d, J = 16Hz, 1H), 11.46 ( bs, 1H).
(4) Preparation of (E) -3- (7-fluoro-1, 2, 3, 4-tetrahydrocyclopenta [b] indol-5-yl) acrylic acid
(E) -3- (7-Fluoro-1,2,3,4-tetrahydrocyclopenta [b] indol-5-yl) acrylic acid methyl ester 0.500 g in tetrahydrofuran 5.0 mL and methanol 5.0 mL suspension in room temperature After adding 5.0 mL of 10% aqueous sodium hydroxide solution, the mixture was stirred at the same temperature for 1.5 hours. After the reaction solution was distilled off under reduced pressure, a 10% aqueous hydrochloric acid solution was added to the residual aqueous layer to adjust the pH to about 2. The mixture was extracted with ethyl acetate, and the extract was dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure to obtain 0.440 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 2.42-2.61 (m, 2H), 2.72 (t, J = 7Hz, 2H), 2.83 (t, J = 7Hz, 2H), 6.63 (d, J = 16Hz , 1H), 7.15 (dd, J = 2Hz, 10Hz, 1H), 7.29 (dd, J = 2Hz, 11Hz, 1H), 8.05 (d, J = 16Hz, 1H), 11.43 (s, 1H), 12.43 ( bs, 1H).

(5) Preparation of (E) -3- [4- (2,4-dichlorobenzyl) -7-fluoro-1, 2, 3, 4-tetrahydrocyclopenta [b] indol-5-yl) acrylic acid
(E) -3- (7-Fluoro-1,2,3,4-tetrahydrocyclopenta [b] indol-5-yl) acrylic acid 0.500 g in tetrahydrofuran 5.0 mL solution under ice-cooling potassium-t-butoxide 0.503 g and 2,4-dichlorobenzyl chloride 0.478 g were sequentially added, followed by stirring at room temperature for 13.5 hours. Water, t-butyl methyl ether, and n-hexane were added to the reaction solution, and the mixture was filtered using Celite. The filtrate was adjusted to pH 2 by adding 10% aqueous hydrochloric acid solution. The mixture was extracted with ethyl acetate, and the extract was dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. The obtained residue was crystallized from ethyl acetate and n-hexane to obtain 0.589 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 2.45-2.51 (m, 2H), 2.77-2.83 (m, 4H), 5.44 (s, 2H), 6.22 (d, J = 15Hz, 1H), 6.28 ( d, J = 8Hz, 1H), 7.09 (dd, J = 2Hz, 11Hz, 1H), 7.24-7.31 (m, 2H), 7.64 (d, J = 15Hz, 1H), 7.67 (d, J = 2Hz, 1H), 12.28 (bs, 1H).
(6) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [4- (2,4-dichlorobenzyl) -7-fluoro-1, 2, 3, 4-tetrahydrocyclopenta [b ] Production of indol-5-yl] acryloyl} amide (compound 1)
(E) -3- [4- (2,4-Dichlorobenzyl) -7-fluoro-1, 2, 3, 4-tetrahydrocyclopenta [b] indol-5-yl) acrylic acid 0.560 g dichloromethane 5.6 mL To the solution, sequentially added 0.354 g of 4,5-dichlorothiophene-2-sulfonamide, 0.292 g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, and 0.186 g of 4-dimethylaminopyridine at room temperature. For 4 hours. A 10% aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.469 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1- [Ill] acryloyl} amide (compound 2)
(1) Preparation of 8-bromo-6-fluoro-2,3,4,9-tetrahydro-1H-carbazole (2-bromo-4-fluorophenyl) hydrazine hydrochloride 5.000 g, 10% aqueous sodium hydroxide solution 13.0 mL A mixture of chloroform (20.0 mL) was stirred at room temperature. The chloroform layer was separated, washed with water, and dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure to obtain (2-bromo-4-fluorophenyl) hydrazine. To (2-bromo-4-fluorophenyl) hydrazine, 20.0 mL of acetic acid and 2.235 g of cyclohexanone were added at room temperature, and the mixture was heated to reflux for 3 minutes. The reaction solution was cooled to room temperature, poured into water, and neutralized by adding a 10% aqueous sodium hydroxide solution. The mixture was extracted with ethyl acetate, washed successively with water and saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was evaporated under reduced pressure, and 3.985 g of the title compound was separated from the obtained residue by silica gel column chromatography.
¹ H-NMR (CDCl ₃ ) δ = 1.82-1.93 (m, 4H), 2.61-2.65 (m, 2H), 2.72-2.76 (m, 2H), 7.02-7.06 (m, 2H), 7.79 (bs, 1H).
(2) (E) -3- (3-Fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) Preparation of acrylic acid methyl ester
Using 3.800 g of 8-bromo-6-fluoro-2, 3, 4, 9-tetrahydro-1H-carbazole and 2.6 mL of acrylic acid methyl ester, the same operation as in Example 1- (3) was carried out. 3.648 g of compound was obtained.
¹ H-NMR (CDCl ₃ ) δ = 1.85-1.94 (m, 4H), 2.65 (t, J = 7Hz, 2H), 2.75 (t, J = 7Hz, 2H), 3.84 (s, 3H), 6.47 ( d, J = 16Hz, 1H), 7.05 (dd, J = 2Hz, 10Hz, 1H), 7.14 (dd, J = 2Hz, 9Hz, 1H), 7.91 (d, J = 16Hz, 1H), 8.02 (bs, 1H).

(3) Production of (E) -3- (3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (3-Fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) Similar to Example 1- (4) using 0.600 g of acrylic acid methyl ester The operation was performed to obtain 0.560 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.80 (m, 4H), 2.56 (bt, 2H), 2.70 (bt, 2H), 6.62 (d, J = 16 Hz, 1H), 7.14 (dd, J = 2Hz, 10Hz, 1H), 7.24 (dd, J = 2Hz, 11Hz, 1H), 7.97 (d, J = 16Hz, 1H), 11.19 (s, 1H), 12.43 (bs, 1H).
(4) Preparation of (E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (3-Fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) Examples using 0.560 g of acrylic acid and 0.507 g of 2,4-dichlorobenzyl chloride The same operation as in 1- (5) was performed to give the title compound (0.708 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.82 (m, 4H), 2.58 (bt, 2H), 2.65 (bt, 2H), 5.39 (s, 2H), 6.18 (d, J = 9Hz, 1H) , 6.23 (d, J = 15Hz, 1H), 7.11 (dd, J = 2Hz, 10Hz, 1H), 7.29-7.32 (m, 2H), 7.64 (d, J = 15Hz, 1H), 7.68 (d, 2Hz , 1H), 12.30 (bs, 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole -1-yl) acrylic acid} amide (compound 2)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.650 g and 4,5-dichloro The same operation as in Example 1- (6) was carried out using 0.397 g of thiophene-2-sulfonamide, to obtain 0.524 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} Example of production of amide (compound 3)
(1) Production of (2-bromophenyl) hydrazine hydrochloride
The same operation as in Example 1- (1) was performed using 10.000 g of 2-bromoaniline to obtain 6.215 g of the title compound.
(2) Preparation of 8-bromo-2,3,4,9-tetrahydro-1H-carbazole Using 2.622 g of (2-bromophenyl) hydrazine hydrochloride and 1.741 g of cyclohexanone, Example 2- (1) and The same operation was performed to obtain 2.741 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.85-1.93 (m, 4H), 2.68 (t, J = 6Hz, 2H), 2.75 (t, J = 6Hz, 2H), 6.94 (t, J = 7.5Hz, 1H), 7.23-7.25 (m, 1H), 7.35-7.39 (m, 2H), 7.85 (bs, 1H).
(3) Production of (E) -3- (6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid methyl ester
The same procedure as in Example 1- (3) was carried out using 2.603 g of 8-bromo-2,3,4,9-tetrahydro-1H-carbazole and 1.9 mL of acrylic acid methyl ester to give the title compound 1.710 got g.
¹ H-NMR (CDCl ₃ ) δ = 1.86-1.95 (m, 4H), 2.70 (t, J = 6Hz, 2H), 2.76 (t, J = 6Hz, 2H), 3.84 (s, 3H), 6.47 ( d, J = 16Hz, 1H), 7.09 (t, J = 8Hz, 1H), 7.32 (d, J = 7Hz, 1H), 7.50 (d, J = 8Hz, 1H), 7.98 (d, J = 16Hz, 1H), 8.06 (bs, 1H).

(4) Production of (E) -3- (6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) Using 0.600 g of acrylic acid methyl ester, the same procedure as in Example 1- (4) was performed. This gave 0.523 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.78-1.84 (m, 4H), 2.66 (t, J = 6Hz, 2H), 2.72 (t, J = 6Hz, 2H), 6.56 (d, J = 16Hz , 1H), 6.97 (d, J = 8Hz, 1H), 7.38-7.41 (m, 2H), 8.05 (d, J = 16Hz, 1H), 11.09 (s, 1H), 12.29 (bs, 1H).
(5) Preparation of (E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) Example 1- (5) using 0.510 g of acrylic acid and 0.496 g of 2,4-dichlorobenzyl chloride. ) To give 0.601 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.80-1.84 (m, 4H), 2.56 (bt, 2H), 2.67 (bt, 2H), 5.39 (s, 2H), 6.15 (d, J = 15Hz, 1H), 6.16 (s, 1H), 7.04 (t, J = 8Hz, 1H), 7.22 (d, J = 7Hz, 1H), 7.28 (dd, J = 2Hz, 9Hz, 1H), 7.51 (d, J = 8Hz, 1H), 7.67 (s, 1H), 7.69 (d, J = 15Hz, 1H).
(6) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl Acrylic acid} amide (compound 3) production
(E) -3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.550 g and 4,5-dichlorothiophene-2- The same operation as in Example 1- (6) was carried out using 0.351 g of sulfonamide to obtain 0.531 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-methyl-6, 7, 8, 9-tetrahydro-5H-carbazole-1- [Ill] acryloyl} amide (compound 4)
(1) Production of (2-bromo-4-methylphenyl) hydrazine hydrochloride
The same operation as in Example 1- (1) was performed using 5.2 g of 2-bromo-4-methylaniline to obtain 4.015 g of the title compound.
(2) Preparation of 8-bromo-6-methyl 2, 3, 4, 9-tetrahydro-1H-carbazole Using 2.000 g of (2-bromo-4-methylphenyl) hydrazine hydrochloride and 0.909 g of cyclohexanone The same operation as in Example 2- (1) was performed to give 1.162 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.83-1.92 (m, 4H), 2.41 (s, 3H), 2.64 (bt, 2H), 2.73 (t, J = 6Hz, 2H), 7.08 (s, 1H) , 7.16 (s, 1H), 7.73 (bs, 1H).
(3) Preparation of (E) -3- (3-methyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid methyl ester
Perform the same operation as in Example 1- (3) using 1.815 g of 8-bromo-6-methyl-2,3,4,9-tetrahydro-1H-carbazole and 1.3 mL of methyl acrylate. To give 1.305 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.86-1.93 (m, 4H), 2.44 (s, 3H), 2.67 (t, J = 6Hz, 2H), 2.74 (t, J = 6Hz, 2H), 3.83 ( s, 3H), 6.45 (d, J = 16Hz, 1H), 7.14 (s, 1H), 7.29 (s, 1H), 7.92 (bs, 1H), 7.94 (d, J = 16Hz, 1H).
(4) Production of (E) -3- (3-methyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (3-Methyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) Similar to Example 1- (4) using 0.499 g of acrylic acid methyl ester. Operation was performed to obtain 0.452 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.75-1.82 (m, 4H), 2.36 (s, 3H), 2.57 (bt, 2H), 2.68 (bt, 2H), 6.56 (d, J = 16Hz, 1H), 7.18 (d, J = 16Hz, 1H), 7.18 (s, 2H), 7.20 (s, 1H), 7.97 (d, J = 16Hz, 1H).

(5) Preparation of (E) -3- [9- (2,4-dichlorobenzyl) -3-methyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (3-Methyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) Examples using 0.430 g of acrylic acid and 0.395 g of 2,4-dichlorobenzyl chloride The same operation as in 1- (5) was performed to give the title compound (0.460 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.77-1.84 (m, 4H), 2.37 (s, 3H), 2.54 (t, J = 5Hz, 2H), 2.64 (t, J = 5Hz, 2H), 5.36 (s, 2H), 6.11-6.15 (m, 2H), 7.07 (s, 1H), 7.26-7.30 (m, 2H), 7.65-7.69 (m, 2H), 12.10 (bs, 1H).
(6) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-methyl-6, 7, 8, 9-tetrahydro-5H-carbazole -1-yl) acrylic acid} amide (compound 4)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-methyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.400 g and 4,5-dichloro The same operation as in Example 1- (6) was carried out using 0.246 g of thiophene-2-sulfonamide, to obtain 0.310 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] Indol-4-yl] acryloyl} amide (Compound 5) Production Example
(1) Preparation of 4-bromo-2-fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] indole (2-bromo-4-fluorophenyl) hydrazine hydrochloride 4.5 g The same operation as in Example 2- (1) was carried out using 2.298 g of heptanone to obtain 2.753 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.75-1.80 (m, 4H), 1.88-1.89 (m, 2H), 2.72 (t, J = 6Hz, 2H), 2.85 (t, J = 6Hz, 2H), 7.01-7.08 (m, 2H), 7.81 (bs, 1H).
(2) (E) -3- (2-Fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] indol-4-yl) Preparation of acrylic acid methyl ester
Example 1- (3) using 2.643 g of 4-bromo-2-fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] indole and 1.7 mL of acrylic acid methyl ester ) To give 1.864 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.76 (m, 4H), 1.90 (m, 2H), 2.74 (t, J = 6Hz, 2H), 2.86 (t, J = 6Hz, 2H), 3.84 (s, 3H), 6.46 (d, J = 16Hz, 1H), 7.04 (dd, J = 2Hz, 10Hz, 1H), 7.15 (d, J = 9Hz, 1H), 7.92 (d, J = 16Hz, 1H), 8.04 (bs, 1H).
(3) (E) -3- (2-Fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] indol-4-yl) Preparation of acrylic acid
(E) -3- (2-Fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] indol-4-yl) Example 1 using 0.600 g of acrylic acid methyl ester -The same operation as in (4) was performed to obtain 0.528 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.66 (m, 4H), 1.83 (m, 2H), 2.67 (bt, 2H), 2.85 (bt, 2H), 6.62 (d, J = 16Hz, 1H) , 7.21-7.28 (m, 2H), 8.04 (d, J = 16Hz, 1H), 11.19 (s, 1H), 12.45 (bs, 1H).

(4) (E) -3- [5- (2,4-Dichlorobenzyl) -2-fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] indol-4-yl) Manufacture of acrylic acid
(E) -3- (2-Fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] indol-4-yl) 0.330 g acrylic acid and 0.24-dichlorobenzyl chloride 0.283 g was used in the same manner as in Example 1- (5) to give the title compound (0.190 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.70 (m, 4H), 1.83 (m, 2H), 2.70 (bt, 2H), 2.79 (bt, 2H), 5.42 (s, 2H), 6.19 (d , J = 15Hz, 1H), 6.29 (d, J = 9Hz, 1H), 7.05 (d, J = 10Hz, 1H), 7.32 (d, J = 8Hz, 2H), 7.36 (d, J = 10Hz, 1H ), 7.59 (d, J = 15Hz, 1H), 7.69 (s, 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-5, 6, 7, 8, 9, 10-hexa Production of hydrocyclohepta [b] indol-4--yl] acryloyl} amide (compound 5)
(E) -3- [5- (2,4-Dichlorobenzyl) -2-fluoro-5, 6, 7, 8, 9, 10-hexahydrocyclohepta [b] indol-4-yl) acrylic acid The same operation as in Example 1- (6) was carried out using 0.190 g and 4,5-dichlorothiophene-2-sulfonamide 0.098 g to obtain the title compound 0.030 g.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydrocycloocta [b] Preparation of [Indol-4-yl] acryloyl} amide (Compound 6)
(1) Preparation of 4-bromo-2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole (2-bromo-4-fluorophenyl) hydrazine hydrochloride with 2.000 g The same operation as in Example 2- (1) was performed using 1.354 g of cyclooctanone to obtain 1.701 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.45 (m, 4H), 1.69 (m, 2H), 1.77 (m, 2H), 2.78 (t, J = 6Hz, 2H), 2.86 (t, J = 6Hz, 2H), 7.02-7.08 (m, 2H), 7.81 (bs, 1H).
(2) (E) -3- (2-Fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) Preparation of acrylic acid methyl ester
Using 4-bromo-2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole 1.644 g and acrylic acid methyl ester 1.0 mL, Example 1- ( The same operation as in 3) was performed to obtain 1.037 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.45 (m, 4H), 1.72 (m, 2H), 1.79 (m, 2H), 2.80 (t, J = 6Hz, 2H), 2.88 (t, J = 6Hz, 2H), 3.84 (s, 3H), 6.47 (d, J = 16Hz, 1H), 7.05 (dd, J = 2Hz, 10Hz, 1H), 7.17 (dd, J = 2Hz, 10Hz, 1H), 7.92 (d , J = 16Hz, 1H), 8.04 (bs, 1H).
(3) (E) -3- (2-Fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) Preparation of acrylic acid
(E) -3- (2-Fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) Examples using 0.500 g of acrylic acid methyl ester The same operation as in 1- (4) was performed to give the title compound (0.470 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.34 (m, 4H), 1.61 (m, 2H), 1.69 (m, 2H), 2.75 (bt, 2H), 2.85 (bt, 2H), 6.63 (d , J = 16Hz, 1H), 7.21-7.28 (m, 2H), 8.04 (d, J = 16Hz, 1H), 11.19 (s, 1H), 12.44 (bs, 1H).

(4) (E) -3- [5- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl Acrylic acid production
(E) -3- (2-Fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) acrylic acid 0.470 g and 2,4-dichlorobenzyl chloride 0.383 g was used in the same manner as in Example 1- (5) to obtain 0.301 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.33 (m, 2H), 1.40 (m, 2H), 1.53 (m, 2H), 1.63 (m, 2H), 2.70 (m, 4H), 5.44 (s , 2H), 6.16 (d, J = 10Hz, 1H), 6.19 (d, J = 16Hz, 1H), 7.05 (dd, J = 2Hz, 10Hz, 1H), 7.29 (dd, J = 2Hz, 8Hz, 2H ), 7.38 (dd, J = 2Hz, 10Hz, 1H), 7.62 (d, J = 16Hz, 1H), 7.68 (d, J = 2Hz, 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexa Production of hydrocycloocta [b] indol-4-yl] acryloyl} amide (Compound 6)
(E) -3- [5- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) acrylic The same operation as in Example 1- (6) was carried out using 0.289 g of the acid and 0.144 g of 4,5-dichlorothiophene-2-sulfonamide to obtain the title compound 0.030 g.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydrocycloocta [b] indole -4-yl] acryloyl} amide (Compound 7) Production Example
(1) Preparation of 4-bromo-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole (2-bromophenyl) hydrazine hydrochloride 4.000 g and cyclooctanone 2.484 g Then, the same operation as in Example 2- (1) was performed to obtain 2.279 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.45 (m, 4H), 1.72 (m, 2H), 1.77 (m, 2H), 2.81-2.89 (m, 4H), 6.95 (t, J = 8Hz, 2H) , 7.24 (m, 1H), 7.41 (d, J = 8Hz, 1H), 7.86 (bs, 1H).
(2) (E) -3- (6, 7, 8, 9, 10, 11-Hexahydro-5H-cycloocta [b] indol-4-yl) Preparation of acrylic acid methyl ester
Similar to Example 1- (3), using 2.200 g of 4-bromo-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole and 1.4 mL of acrylic acid methyl ester The title compound 1.404 g was obtained.
¹ H-NMR (DMSO-d ₆ ) δ = 1.37 (m, 4H), 1.63 (m, 2H), 1.71 (m, 2H), 2.79 (t, J = 6Hz, 2H), 2.87 (t, J = 6Hz, 2H), 3.75 (s, 3H), 6.67 (d, J = 16Hz, 1H), 6.97 (t, J = 8Hz, 1H), 7.42 (d, J = 7Hz, 1H), 7.47 (d, J = 7Hz, 1H), 7.13 (d, J = 16Hz, 1H), 11.10 (bs, 1H).

(3) Production of (E) -3- (2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) acrylic acid
(E) -3- (6, 7, 8, 9, 10, 11-Hexahydro-5H-cycloocta [b] indol-4-yl) Example 1- (4) using 1.400 g of acrylic acid methyl ester ) To give 1.316 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.36 (m, 4H), 1.63 (m, 2H), 1.70 (m, 2H), 2.79 (bt, 2H), 2.87 (bt, 2H), 6.58 (d , J = 16Hz, 1H), 6.96 (t, J = 8Hz, 1H), 7.36 (d, J = 8Hz, 2H), 7.44 (d, J = 8Hz, 1H), 8.04 (d, J = 16Hz, 1H ), 11.06 (s, 1H), 12.40 (bs, 1H).
(4) (E) -3- [5- (2,4-Dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) acrylic acid Manufacturing
(E) -3- (6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) Use 0.400 g of acrylic acid and 0.348 g of 2,4-dichlorobenzyl chloride. In the same manner as in Example 1- (5), the title compound (1.598 g) was obtained.
¹ H-NMR (DMSO-d ₆ ) δ = 1.33 (m, 2H), 1.40 (m, 2H), 1.53 (m, 2H), 1.63 (m, 2H), 2.70 (m, 4H), 5.44 (s , 2H), 6.16 (d, J = 10Hz, 1H), 6.19 (d, J = 16Hz, 1H), 7.05 (dd, J = 2Hz, 10Hz, 1H), 7.29 (dd, J = 2Hz, 8Hz, 2H ), 7.38 (dd, J = 2Hz, 10Hz, 1H), 7.62 (d, J = 16Hz, 1H), 7.68 (d, J = 2Hz, 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydrocycloocta [ b] Indol-4-yl] acryloyl} amide (compound 7)
(E) -3- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl) acrylic acid 1.598 g and 4 , 5-dichlorothiophene-2-sulfonamide 0.331 g was used in the same manner as in Example 1- (6) to give the title compound 0.184 g.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3- b] Indol-6-yl] acryloyl} amide (Compound 8) Production Example
(1) Preparation of 6-bromo-8-fluoro-1, 3, 4, 5-tetrahydropyrano [4,3-b] indole (2-bromo-4-fluorophenyl) hydrazine hydrochloride (2.000 g) and tetrahydro- The same operation as in Example 1- (2) was carried out using 1.074 g of 4H-pyran-4-one to obtain 1.002 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 2.88-2.90 (m, 2H), 4.05 (t, J = 5Hz, 2H), 4.83 (s, 2H), 6.99 (dd, J = 2Hz, 9Hz, 2H), 7.09 (dd, J = 2Hz, 9Hz, 1H), 8.02 (bs, 1H).
(2) Preparation of (E) -3- (8-fluoro-1, 3, 4, 5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid methyl ester
Similar to Example 1- (3), using 1.000 g of 6-bromo-8-fluoro-1, 3, 4, 5-tetrahydropyrano [4,3-b] indole and 0.67 mL of acrylic acid methyl ester The title compound 0.517 g was obtained.
¹ H-NMR (DMSO-d ₆ ) δ = 2.82 (t, J = 5Hz, 2H), 3.75 (s, 3H), 3.93 (t, J = 5Hz, 2H), 4.73 (s, 2H), 6.77 ( d, J = 16Hz, 1H), 7.22 (dd, J = 2Hz, 9Hz, 1H), 7.40 (dd, J = 2Hz, 11Hz, 1H), 8.11 (d, J = 16Hz, 1H), 11.52 (bs, 1H).

(3) (E) -3- (8-Fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl) Preparation of acrylic acid
3- (8-Fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid methyl ester using 0.500 g and Example 1- (4) The same operation was performed to obtain 0.475 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 2.81 (t, J = 5Hz, 4H), 3.92 (t, J = 5Hz, 2H), 4.73 (s, 2H), 6.65 (d, J = 16Hz, 1H ), 7.20 (dd, J = 2Hz, 9Hz, 1H), 7.35 (dd, J = 2Hz, 11Hz, 1H), 8.04 (d, J = 16Hz, 1H), 11.49 (s, 1H), 12.50 (bs, 1H).
(4) (E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl) acrylic Acid production
(E) -3- (8-Fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) 0.460 g of acrylic acid and 0.413 g of 2,4-dichlorobenzyl chloride Were used and the same operation as in Example 1- (5) was carried out to give 0.442 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 2.71 (bt, 2H), 3.95 (t, J = 6Hz, 2H), 4.78 (s, 2H), 5.43 (s, 2H), 6.18 (d, J = 8Hz, 1H), 6.23 (d, J = 16Hz, 1H), 7.15 (dd, J = 3Hz, 11Hz, 1H), 7.28-7.34 (m, 2H), 7.63 (d, J = 16Hz, 1H), 7.68 (d, 2Hz, 1H), 12.29 (bs, 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4 , 3-b] Indol-6-yl] acryloyl} amide (Compound 8)
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.300 g And 0.182 g of 4,5-dichlorothiophene-2-sulfonamide were used in the same manner as in Example 1- (6) to obtain 0.338 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -1,3,4,5-tetrahydropyrano [4,3-b] indole- 6-yl] acryloyl} amide (Compound 9) Production Example
(1) Preparation of 6-bromo-1, 3, 4, 5-tetrahydropyrano [4,3-b] indole (2-bromophenyl) hydrazine hydrochloride 6.000 g and tetrahydro-4H-pyran-4-one 3.212 g was used in the same manner as in Example 1- (2) to obtain 0.849 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 2.90 (t, J = 5Hz, 2H), 4.06 (t, J = 5Hz, 2H), 4.89 (s, 2H), 6.96 (t, J = 8Hz, 1H), 7.30 (m, 2H), 8.07 (bs, 1H).
(2) Preparation of (E) -3- (1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl) acrylic acid methyl ester
The same procedure as in Example 1- (3) was performed using 0.800 g of 6-bromo-1, 3, 4, 5-tetrahydropyrano [4,3-b] indole and 0.6 mL of methyl acrylate. The title compound 0.408 g was obtained.
¹ H-NMR (CDCl ₃ ) δ = 2.90 (t, J = 5Hz, 2H), 3.84 (s, 3H), 4.06 (t, J = 5Hz, 2H), 4.91 (s, 2H), 6.49 (d, J = 16Hz, 1H), 7.11 (d, J = 8Hz, 1H), 7.36 (d, J = 7Hz, 1H), 7.41 (d, J = 8Hz, 1H), 7.99 (d, J = 16Hz, 1H) , 8.25 (bs, 1H).

(3) Production of (E) -3- (1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl) acrylic acid
(E) -3- (1, 3, 4, 5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid methyl ester using 0.100 g and Example 1- (4) The same operation was performed to obtain 0.065 g of the title compound.
¹ H-NMR (CD ₃ OD) δ = 2.89 (t, J = 5Hz, 4H), 4.04 (t, J = 5Hz, 2H), 4.85 (s, 2H), 6.55 (d, J = 16Hz, 1H) , 7.03 (d, J = 8Hz, 1H), 7.38 (d, J = 8Hz, 2H), 8.09 (d, J = 16Hz, 1H).
(4) (E) -3- [5- (2,4-Dichlorobenzyl)-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl) Preparation of acrylic acid
(E) -3- (1, 3, 4, 5-tetrahydropyrano [4,3-b] indol-6-yl) using 0.182 g of acrylic acid and 0.176 g of 2,4-dichlorobenzyl chloride, The same operation as in Example 1- (5) was performed to give the title compound (0.135 g).
¹ H-NMR (DMSO-d ₆ ) δ = 2.70 (bt, 2H), 3.96 (bt, 2H), 4.82 (s, 2H), 5.43 (s, 2H), 6.15 (d, J = 16Hz, 1H) , 6.18 (d, J = 9Hz, 1H), 7.07 (t, J = 7Hz, 1H), 7.25-7.30 (m, 2H), 7.49 (d, J = 8Hz, 2H), 7.69 (d, J = 16Hz , 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl)-1, 3, 4, 5-tetrahydropyrano [4, 3-b ] Production of indol-6-yl] acryloyl} amide (compound 9)
(E) -3- [5- (2,4-Dichlorobenzyl) -1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.130 g and 4, 5 -The same operation as in Example 1- (6) was carried out using 0.083 g of dichlorothiophene-2-sulfonamide to obtain 0.110 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9- Production Example of Azafluoren-8-yl] acryloyl} amide (Compound 10)
(1) Preparation of 8-bromo-6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluorene (2-bromo-4-fluorophenyl) hydrazine hydrochloride 6.000 g and 4-oxothiane The same operation as in Example 1- (2) was carried out using 3.740 g, to obtain 1.934 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 3.00 (t, J = 5Hz, 2H), 3.04 (t, J = 5Hz, 2H), 3.77 (s, 2H), 7.04-7.10 (m, 2H), 7.91 ( bs, 1H).
(2) Production of 8-bromo-9- (2,4-dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluorene
8-Bromo-6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluorene in a solution of 6.000 g of tetrahydrofuran in 6.0 mL of tetrahydrofuran at room temperature with 0.282 g of potassium t-butoxide and 2,4-dichlorobenzyl chloride After sequentially adding 0.492 g, the mixture was stirred at the same temperature for 30 minutes and at 50 ° C. for 1.5 hours. The reaction solution was cooled to room temperature and then poured into a saturated aqueous ammonium chloride solution. After extraction with toluene, the extract was washed successively with water and saturated brine, and dried over anhydrous sodium sulfate. From the obtained residue, 0.525 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 2.81 (bt, 2H), 3.00 (t, J = 6Hz, 2H), 3.81 (s, 3H), 5.69 (s, 2H), 6.12 (d, J = 8Hz, 1H), 7.04-7.11 (m, 3H), 7.42 (s, 1H).
(3) (E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluoren-8-yl] acrylic acid Production of methyl ester
8-Bromo-9- (2,4-dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluorene In a solution of 0.525 g of acetonitrile in 5.3 mL of acetonitrile, 0.99 mL of triethylamine, acrylic After adding 0.21 mL of acid methyl ester, 0.054 g of tri- (o-tolyl) phosphine and 0.013 g of palladium (II) acetate at room temperature, the mixture was heated to reflux for 12.5 hours. The reaction mixture was cooled to room temperature, saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was evaporated under reduced pressure, and 0.300 g of the title compound was separated from the obtained residue by silica gel column chromatography (ethyl acetate-chloroform).
¹ H-NMR (CDCl ₃ ) δ = 2.85 (t, J = 6Hz, 2H), 3.03 (t, J = 6Hz, 2H), 3.73 (s, 3H), 3.84 (s, 2H), 5.32 (s, 2H), 6.19 (d, J = 15Hz, 1H), 6.26 (d, J = 10Hz, 1H), 7.19 (d, J = 6Hz, 1H), 7.17 (d, J = 16Hz, 1H).

(4) (E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluoren-8-yl] acrylic acid Manufacturing of
(E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluoren-8-yl] Acrylic acid methyl ester 0.130 To a suspension of g in tetrahydrofuran (1.3 mL) and methanol (1.3 mL) was added 10% aqueous sodium hydroxide solution (0.8 mL) at room temperature, and the mixture was stirred at the same temperature for 15.5 hr. After the reaction solution was distilled off under reduced pressure, a 10% aqueous hydrochloric acid solution was added to the residual aqueous layer to adjust the pH to about 2. After extraction with ethyl acetate, the extract was washed successively with water and saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure to obtain 0.100 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 2.82 (bt, 2H), 2.98 (t, J = 6Hz, 2H), 3.81 (s, 2H), 5.41 (s, 2H), 6.16 (d, J = 8Hz, 1H), 6.22 (d, J = 15Hz, 1H), 7.13 (d, J = 10Hz, 1H), 7.29 (dd, J = 2Hz, 11Hz, 1H), 7.40 (d, J = 6Hz, 1H) , 7.60 (d, J = 15Hz, 1H), 7.69 (d, J = 2Hz, 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia -9-Azafluoren-8-yl] acryloyl} amide (Compound 10)
(E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluoren-8-yl] of acrylic acid 0.090 g To a 2.0 mL solution of dichloromethane, 0.054 g of 4,5-dichlorothiophene-2-sulfonamide, 0.045 g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, and 0.029 g of 4-dimethylaminopyridine were sequentially added at room temperature. And stirred at the same temperature for 6 hours. A 10% aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.081 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6-fluoro-3, 3-dioxo-2, 3, 4, 9-tetrahydro- 1H-3λ ⁶ -Thia-9-azafluoren-8-yl] acryloyl} amide (Compound 11) Production Example
(1) (E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-3, 3-dioxo-2, 3, 4, 9-tetrahydro-1H-3λ ⁶ -thia-9- Azafluoren-8-yl] acryloyl acid methyl ester
(E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-1, 2, 4, 9-tetrahydro-3-thia-9-azafluoren-8-yl] Acrylic acid methyl ester 0.160 To a suspension of g in tetrahydrofuran 1.6 mL-methanol 1.6 mL-water 1.6 mL was added 0.212 g of oxone at room temperature, and the mixture was stirred for 18 hours. To the reaction solution was added 2M aqueous sodium carbonate solution, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated aqueous ammonium chloride solution and dried over anhydrous sodium sulfate. From the obtained residue, 0.147 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 3.27 (t, J = 6Hz, 2H), 3.36 (t, J = 6Hz, 2H), 3.74 (s, 3H), 4.36 (s, 2H), 5.38 (s, 2H), 6.21 (d, J = 16Hz, 1H), 6.28 (d, J = 8Hz, 1H), 7.02 (dd, J = 2Hz, 10Hz, 1H), 7.11-7.13 (m, 2H), 7.52 (d , J = 2Hz, 1H), 7.68 (d, J = 15Hz, 1H).
(2) (E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-3, 3-dioxo-2, 3, 4, 9-tetrahydro-1H-3λ ⁶ -thia-9- Azafluoren-8-yl] acryloyl acid production
(E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-3, 3-dioxo-2, 3, 4, 9-tetrahydro-1H-3λ ⁶ -thia-9-azafluorene- The same operation as in Example 10- (4) was carried out using 0.147 g of 8-yl] acryloyl acid methyl ester to obtain 0.142 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 3.27 (t, J = 6Hz, 2H), 3.36 (t, J = 6Hz, 2H), 4.36 (s, 2H), 5.38 (s, 2H), 6.21 ( d, J = 16Hz, 1H), 6.28 (d, J = 8Hz, 1H), 7.02 (dd, J = 2Hz, 10Hz, 1H), 7.11-7.13 (m, 2H), 7.52 (d, J = 2Hz, 1H), 7.68 (d, J = 15Hz, 1H), 11.01 (bs, 1H).
(3) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6-fluoro-3, 3-dioxo-2, 3, 4, 9 Of 4-Tetrahydro-1H-3λ ⁶ -thia-9-azafluoren-8-yl] acryloyl} amide (Compound 11)
(E) -3- [9- (2,4-Dichlorobenzyl) -6-fluoro-3, 3-dioxo-2, 3, 4, 9-tetrahydro-1H-3λ ⁶ -thia-9-azafluorene- The same operation as in Example 10- (5) was carried out using 0.142 g of 8-yl] acryloyl acid and 0.078 g of 4,5-dichlorothiophene-2-sulfonamide to obtain the title compound 0.108 g.

5- (2,4-dichlorobenzyl) -6-[(E) -3- (4,5-dichlorothiophene-2-sulfonylamino) -3-oxopropenyl] -8-fluoro-1, 3, 4, Production example of 5-tetrahydropyrido [4,3-b] indole-2-carboxylic acid ethyl ester (compound 12)
(1) Preparation of 6-bromo-8-fluoro-1, 3, 4, 5-tetrahydropyrido [4, 3-b] indole-2-carboxylic acid ethyl ester (2-bromo-4-fluorophenyl) hydrazine A 10.0 mL acetic acid solution of 1.000 g hydrochloride and 0.918 g 4-oxopiperidine-1-carboxylic acid ethyl ester was stirred at 80 ° C. for about 2 hours, 0.1 mL sulfuric acid was added, and the mixture was further stirred at 80 ° C. for 16 hours. After cooling the reaction solution to room temperature, water was added to the reaction solution. The precipitated solid was collected by filtration, washed with water and dried to give 0.951 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.31 (t, J = 7Hz, 3H), 2.87 (bt, 2H), 3.86 (bt, 2H), 4.20 (q, J = 7Hz, 3H), 4.62 (s, 2H), 7.05-7.12 (m, 2H), 8.04 (bs, 1H).
(2) Preparation of 6-bromo-5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrido [4, 3-b] indole-2-carboxylic acid ethyl ester
Using 0.930 g of 6-bromo-8-fluoro-1, 3, 4, 5-tetrahydropyrido [4,3-b] indole-2-carboxylic acid ethyl ester and 0.639 g of 2,4-dichlorobenzyl chloride In the same manner as in Example 10- (2), 1.094 g of the title compound was obtained.
¹ H-NMR (CDCl ₃ ) δ = 1.30 (bt, 3H), 2.66 (bt, 2H), 3.84 (bt, 2H), 4.20 (q, J = 7Hz, 3H), 4.66 (bs, 2H), 5.67 (s, 2H), 6.10 (d, J = 8Hz, 1H), 7.04-7.11 (m, 3H), 7.42 (d, J = 2Hz, 1H).
(3) 5- (2,4-Dichlorobenzyl) -8-fluoro-6-[(E) -2-methoxycarbonylvinyl] -1, 3, 4, 5-tetrahydropyrido [4, 3-b] Production of indole-2-carboxylic acid ethyl ester
6-bromo-5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrido [4, 3-b] indole-2-carboxylic acid ethyl ester 0.500 g and acrylic acid The same operation as in Example 10- (3) was carried out using 0.18 mL of methyl to obtain 0.401 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.31 (bt, 3H), 2.70 (bt, 2H), 3.73 (s, 3H), 3.88 (br, 2H), 4.21 (q, J = 7Hz, 3H), 4.69 (bs, 2H), 5.35 (s, 2H), 6.19 (d, J = 16Hz, 1H), 6.24 (d, J = 8Hz, 1H), 6.97 (dd, J = 3Hz, 10Hz, 1H), 7.08 ( dd, J = 2Hz, 8Hz, 1H), 7.18 (dd, J = 3Hz, 9Hz, 1H), 7.49 (d, J = 2Hz, 1H), 7.71 (d, J = 15Hz, 1H).

(4) 5- (2,4-Dichlorobenzyl) -8-fluoro-6-[(E) -2-methoxycarbonylvinyl] -1, 3, 4, 5-tetrahydropyrido [4, 3-b] Production of indole-2-carboxylic acid
5- (2,4-Dichlorobenzyl) -8-fluoro-6-[(E) -2-methoxycarbonylvinyl] -1, 3, 4, 5-tetrahydropyrido [4, 3-b] indole-2 -The same operation as in Example 10- (4) was performed using 0.358 g of carboxylic acid ethyl ester to obtain 0.312 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.21 (t, J = 7Hz, 3H), 2.67 (bt, 2H), 3.75 (t, J = 6Hz, 2H), 4.09 (q, J = 7Hz, 3H ), 4.60 (bs, 2H), 5.43 (s, 2H), 6.19 (d, J = 8Hz, 1H), 6.22 (d, J = 15Hz, 1H), 7.05 (dd, J = 2Hz, 11Hz, 1H) , 7.29 (dd, J = 2Hz, 9Hz, 1H), 7.40 (dd, J = 2Hz, 9Hz, 1H), 7.47 (d, J = 16Hz, 1H), 7.67 (d, J = 2Hz, 1H).
(5) 5- (2,4-dichlorobenzyl) -6- [3- (4,5-dichlorothiophene-2-sulfonylamino)-(E) -3-oxopropenyl] -8-fluoro-1, 3 Of 4,4,5-tetrahydropyrido [4,3-b] indole-2-carboxylic acid ethyl ester (compound 12)
5- (2,4-Dichlorobenzyl) -8-fluoro-6-[(E) -2-methoxycarbonylvinyl] -1, 3, 4, 5-tetrahydropyrido [4, 3-b] indole-2 -The same operation as in Example 10- (5) was performed using 0.300 g of carboxylic acid and 0.156 g of 4,5-dichlorothiophene-2-sulfonamide to obtain 0.328 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6- (1,3-dioxolan-2-yl) -3-fluoro-6, Example of production of 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} amide (compound 13)
(1) Preparation of 8-bromo- (1,3-dioxolan-2-yl) -butyl-6-fluoro-2, 3, 4, 9-tetrahydro-1H-carbazole (2-bromo-4-fluorophenyl) The same operation as in Example 1- (2) was carried out using 4.000 g of hydrazine hydrochloride and 3.046 g of 1,4-cyclohexadione monoethylene acetal to obtain 2.400 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 2.07 (t, J = 6Hz, 2H), 2.89 (s, 2H), 2.96 (t, J = 7Hz, 2H), 4.05-4.09 (m, 4H), 7.01- 7.06 (m, 2H), 7.25 (s, 1H), 7.91 (bs, 1H).
(2) (E) -3- [6- (1,3-Dioxolan-2-yl) -butyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl)] acrylic Production of acid methyl ester
Example using 2.390 g of 8-bromo- (1,3-dioxolan-2-yl) -butyl-6-fluoro-2,3,4,9-tetrahydro-1H-carbazole and 1.3 mL of methyl acrylate The same operation as in 1- (3) was performed to give 1.804 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 2.08 (t, J = 6Hz, 2H), 2.91 (s, 2H), 2.96 (t, J = 7Hz, 2H), 3.84 (s, 3H), 4.05-4.08 ( m, 4H), 6.46 (d, J = 16Hz, 1H), 7.05-7.11 (m, 2H), 7.26 (s, 1H), 7.89 (d, J = 16Hz, 1H), 8.16 (bs, 1H).

(3) (E) -3- [6- (1,3-Dioxolan-2-yl) -butyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl)] acrylic Acid production
(E) -3- [6- (1,3-Dioxolan-2-yl) -butyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl)] acrylic acid methyl ester The same operation as in Example 1- (4) was performed using 1.400 g, to obtain 1.186 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.94 (m, 2H), 2.77-2.83 (m, 4H), 3.94 (s, 4H), 6.62 (d, J = 16Hz, 1H), 7.17 (d, J = 9Hz, 1H), 7.30 (d, J = 8Hz, 1H), 8.00 (d, J = 16Hz, 1H), 11.31 (bs, 1H).
(4) (E) -3- [6- (1,3-Dioxolan-2-yl) -9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H -Carbazol-1-yl] Production of acrylic acid
(E) -3- [6- (1,3-Dioxolan-2-yl) -butyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl)] acrylic acid 1.180 g Was used in the same manner as in Example 1- (5), to give 1.206 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.96 (t, J = 8Hz, 2H), 2.72 (t, J = 8Hz, 2H), 2.85 (s, 2H), 3.94 (s, 4H), 6.16 ( d, J = 9Hz, 1H), 6.22 (d, J = 15Hz, 1H), 7.12 (d, J = 11Hz, 1H), 7.29 (d, J = 10Hz, 1H), 7.60 (d, J = 15Hz, 1H), 7.68 (s, 1H).
(5) {(E) -3- [9- (2,4-Dichlorobenzyl) -6- (1,3-dioxolan-2-yl) -3-fluoro-6, 7, 8, 9-tetrahydro- 5H-Carbazol-1-yl] acryloyl} amide (Compound 13)
(E) -3- [6- (1,3-Dioxolan-2-yl) -9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole- 1-yl] Acrylic acid 0.300 g 4,5-dichlorothiophene-2-sulfonamide 0.152 g was used in the same manner as in Example 1- (6) to obtain the title compound 0.295 g.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6-oxo-6, 7, 8, 9-tetrahydro-5H- Production example of carbazol-1-yl] acryloyl} amide (compound 14)
{(E) -3- [9- (2,4-Dichlorobenzyl) -6- (1,3-dioxolan-2-yl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole 1-yl] acryloyl} amide 0.195 g in tetrahydrofuran (5.0 mL) was added with 10% aqueous hydrochloric acid (0.5 mL) at room temperature, and then heated under reflux for 2.5 hours. After the reaction solution was cooled to room temperature, water was added. The precipitated crystals were collected by filtration, washed with water and dried to give the title compound (0.107 g).

4, 5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2, 4-dichlorobenzyl) -3-fluoro-6-hydroxy-6, 7, 8, 9-tetrahydro-5H- Production example of carbazol-1-yl] acryloyl} amide (compound 15)
4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6-oxo-6, 7, 8, 9-tetrahydro-5H- To a solution of 0.368 g of carbazol-1-yl] acryloyl} amide in 1.7 mL of tetrahydrofuran was added 0.005 g of sodium borohydride under ice cooling, and the mixture was stirred for 6.5 hours. Acetone and saturated aqueous ammonium chloride solution were added to the reaction solution. Precipitated crystals were collected by filtration, washed with water, and dried to give the title compound (0.204 g).

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [6-tert-butyl-9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro- Production example of 5H-carbazol-1-yl] acryloyl} amide (Compound 16)
(1) Preparation of 8-bromo-3-tert-butyl-6-fluoro-2,3,4,9-tetrahydro-1H-carbazole (2-bromo-4-fluorophenyl) hydrazine hydrochloride 2.000 g and 4- The same operation as in Example 2- (1) was carried out using 1.655 g of tert-butylcyclohexanone to obtain 2.525 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 0.99 (s, 9H), 1.52 (m, 2H), 2.13 (m, 1H), 2.35 (m, 1H), 2.72-2.80 (m, 3H), 7.03-7.08 (m, 2H), 7.80 (bs, 1H).
(2) Preparation of (E) -3- (6-tert-butyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid methyl ester
Similar to Example 1- (3) using 2.510 g of 8-bromo-3-tert-butyl-6-fluoro-2,3,4,9-tetrahydro-1H-carbazole and 1.4 mL of methyl acrylate The operation was performed to obtain 1.400 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.00 (s, 9H), 1.52 (m, 2H), 2.14 (m, 1H), 2.56 (m, 1H), 2.73-2.80 (m, 3H), 3.84 (s , 3H), 6.46 (d, J = 16Hz, 1H), 7.05 (d, J = 10Hz, 1H), 7.16 (d, J = 9Hz, 1H), 7.91 (d, J = 16Hz, 1H), 8.09 ( bs, 1H).

(3) Preparation of (E) -3- (6-tert-butyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (6-tert-Butyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid methyl ester using 1.400 g of Example 1 The same operation as in (4) was performed to obtain 1.319 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 0.96 (s, 9H), 1.40 (m, 2H), 1.98 (m, 1H), 2.07 (m, 1H), 2.50-2.77 (m, 2H), 2.78 (m, 1H), 6.61 (d, J = 16Hz, 1H), 7.19 (d, J = 10Hz, 1H), 7.23 (d, J = 10Hz, 1H), 8.00 (d, J = 16Hz, 1H), 11.20 (bs, 1H).
(4) (E) -3- [6-tert-Butyl-9- (2, 4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic Acid production
(E) -3- (6-tert-butyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) 0.700 g of acrylic acid and 0.520 g of 2,4-dichlorobenzyl chloride And the same operation as in Example 1- (5) was carried out to obtain 0.589 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.00 (s, 9H), 1.39-1.43 (m, 2H), 2.07 (m, 1H), 2.33 (m, 1H), 2.53 (m, 1H), 2.53 -2.75 (m, 2H), 5.37 (s, 2H), 6.14 (d, J = 8Hz, 1H), 6.21 (d, J = 15Hz, 1H), 7.09 (dd, J = 2Hz, 10Hz, 1H), 7.26-7.34 (m, 2H), 7.62 (d, J = 15Hz, 1H), 7.66 (d, J = 2Hz, 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [6-tert-butyl-9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9 -Tetrahydro-5H-carbazol-1-yl] acryloyl} amide (Compound 16)
(E) -3- [6-tert-Butyl-9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic acid 0.260 g The same operation as in Example 1- (6) was carried out using 0.140 g of 4,5-dichlorothiophene-2-sulfonamide, to obtain 0.196 g of the title compound.

4,5-Dimethylthiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Il] acryloyl} amide (compound 17)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.128 g in dichloromethane 3.0 mL solution At room temperature, 0.070 g of 4,5-dimethylthiophene-2-sulfonamide, 0.070 g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and 0.045 g of 4-dimethylaminopyridine were added in that order at the same temperature. Stir for hours. A 10% aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.121 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).

Thiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} amide Production Example of (Compound 18)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.300 g and thiophene-2-sulfone The same operation as in Example 17 was carried out using 0.129 g of amide, to obtain 0.240 g of the title compound.

N-{(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -4-methoxybenzene Production example of sulfonamide (compound 19)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.261 g and 4-methoxybenzenesulfone The same operation as in Example 17 was carried out using 0.139 g of amide, to obtain 0.152 g of the title compound.

Benzo [b] thiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Acryloyl} amide (Compound 20) production example
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.261 g and benzo [b] thiophene The same operation as in Example 17 was performed using 0.147 g of -2-sulfonamide to obtain 0.171 g of the title compound.

5-Bromo N-{(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -2 -Methoxybenzenesulfonamide (Compound 21) Production Example
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.200 g and 5-bromo-2 The same operation as in Example 17 was carried out using 0.140 g of -methoxybenzenesulfonamide to obtain 0.199 g of the title compound.

Benzo [1, 2, 5] thiadiazole-4-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole -1-yl] acryloyl} amide (Compound 22)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.209 g and benzo [1, 2 , 5] Thiadiazole-4-sulfonamide 0.118 g was used in the same manner as in Example 17 to obtain the title compound 0.116 g.

Naphthalene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} amide Production Example of (Compound 23)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.230 g and naphthalene-2-sulfone The same operation as in Example 17 was performed using 0.125 g of amide, to obtain 0.190 g of the title compound.

(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] -N- (3-methylisoxazole -5-yl) acrylamide (compound 24) production example
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.230 g and 3-methylisoxa The same operation as in Example 17 was carried out using 0.077 g of zol-5-ylamine to obtain 0.169 g of the title compound.

(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] -N- (3,4-dimethyliso Example of production of xazol-5-yl) acrylamide (compound 25)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.300 g and 3, 4-methyl The same operation as in Example 17 was carried out using 0.088 g of isoxazol-5-ylamine to obtain 0.137 g of the title compound.

N- (4-Bromo-3-methylisoxazol-5-yl) -3-[9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H- Production example of carbazol-1-yl] acrylamide (compound 26)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.300 g suspended in dichloromethane 6.0 mL To the solution, 0.152 g of 4-bromo-3-methylisoxazol-5-ylamine, 0.4 mL of triethylamine, and 0.366 g of 2-chloro-1-methylpyridinium iodide were added under ice cooling, followed by stirring at room temperature for 21.5 hours. did. The reaction mixture was poured into 5% aqueous citric acid solution and extracted with ethyl acetate. The extract was washed successively with water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.134 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).

(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] -N- (5-methylisoxazole -3-yl) acrylamide (compound 27) production example
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid (0.300 g) and 3-methylisoxa The same operation as in Example 17 was performed using 0.077 g of zol-5-ylamine to obtain 0.207 g of the title compound.

(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] -N-tert-butoxycarbonyl-2- Production Example of (Ethylaminosulfonylphenyl) acrylamide (Compound 28)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.500 g and 2- (N- tert-Butoxycarbonyl-2-ethylaminosulfonyl) aniline was used in the same manner as in Example 26 to obtain the title compound (0.398 g).

N-{(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -4-fluorobenzene Production example of sulfonamide (Compound 29)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.200 g and 4-fluorobenzenesulfone The same operation as in Example 17 was carried out using 0.100 g of amide, to obtain 0.195 g of the title compound.

N-{(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acroyl} -3, 4- Production example of difluorobenzenesulfonamide (Compound 30)
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.200 g and 3, 4-difluoro The same operation as in Example 17 was carried out using 0.110 g of benzenesulfonamide to obtain 0.156 g of the title compound.

5-Bromo N-{(E) -3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -2 -Methoxybenzenesulfonamide (Compound 31) Production Example
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.200 g and 5-bromo-2 The same operation as in Example 17 was carried out using 0.120 g of -methoxybenzenesulfonamide to obtain 0.134 g of the title compound.

Benzo [b] thiophene-2-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} amide Production Example of (Compound 32)
(E) -3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.250 g and benzo [b] thiophene-2-sulfone The same operation as in Example 17 was carried out using 0.147 g of amide, to obtain 0.212 g of the title compound.

5-Bromo N-{(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -2-methoxybenzenesulfone Example of production of amide (compound 33)
(E) -3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.110 g and 5-bromo-2-methoxybenzenesulfone The same operation as in Example 17 was carried out using 0.080 g of amide, to obtain 0.119 g of the title compound.

Benzo [1, 2, 5] thiadiazole-4-sulfonic acid {(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Examples of acryloyl} amide (compound 34)
(E) -3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.100 g and benzo [1, 2, 5] thiadiazole The same operation as in Example 17 was performed using 0.059 g of -4-sulfonamide, to obtain 0.060 g of the title compound.

N-{(E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -4-fluorobenzenesulfonamide (compound 35) Production example
(E) -3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.200 g and 4-fluorobenzenesulfonamide 0.098 g And the same operation as in Example 17 was carried out to obtain 0.216 g of the title compound.

N-{(E) -3- [9- (2, 4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} -3, 4-difluorobenzenesulfonamide Production Example of (Compound 36)
(E) -3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.200 g and 3,4-difluorobenzenesulfonamide 0.098 g was used for the same operation as in Example 17, and 0.211 g of the title compound was obtained.

5-Bromo N-{(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indole-6- [Ill] acryloyl} -2-methoxybenzenesulfonamide (Compound 37)
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.100 g And 0.070 g of 5-bromo-2-methoxybenzenesulfonamide were used in the same manner as in Example 17 to obtain 0.110 g of the title compound.

Benzo [1, 2, 5] thiadiazole-4-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4 , 3-b] Indol-6-yl] acryloyl} -2-methoxybenzenesulfonamide (Compound 38)
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.250 g And benzo [1, 2, 5] thiadiazole-4-sulfonamide 0.141 g were used in the same manner as in Example 17 to obtain 0.256 g of the title compound.

N-{(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] acryloyl } -4-Fluorobenzenesulfonamide (Compound 39) Production Example
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.200 g And 0.109 g of 4-fluorobenzenesulfonamide were used in the same manner as in Example 17 to obtain 0.154 g of the title compound.

N-{(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] acryloyl } -3, 4-Difluorobenzenesulfonamide (Compound 40) production example
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.200 g And 0.109 g of 3,4-difluorobenzenesulfonamide were used in the same manner as in Example 17 to obtain 0.136 g of the title compound.

Benzo [1, 2, 5] thiadiazole-4-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -1, 3, 4, 5-tetrahydropyrano [4, 3-b ] Indol-6-yl] acryloyl} amide (compound 41) production example
(E) -3- [5- (2,4-dichlorobenzyl) -1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.200 g and benzo [1 , 2, 5] thiadiazole-4-sulfonamide 0.110 g was used in the same manner as in Example 17 to obtain 0.240 g of the title compound.

N-{(E) -3- [5- (2,4-dichlorobenzyl) -1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] acryloyl} -4- Production example of fluorobenzenesulfonamide (Compound 42)
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.200 g And 0.097 g of 4-fluorobenzenesulfonamide were used in the same manner as in Example 17 to obtain 0.215 g of the title compound.

N-{(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] acryloyl } Production example of 3,4-difluorobenzenesulfonamide (Compound 43)
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.200 g And 0.14 g of 3,4-difluorobenzenesulfonamide were used in the same manner as in Example 17 to obtain 0.165 g of the title compound.

N-{(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl ] Acryloyl} -4-fluorobenzenesulfonamide (Compound 44)
(E) -3- [5- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] acrylic acid The same operation as in Example 17 was carried out using 0.159 g and 4-fluorobenzenesulfonamide 0.074 g to obtain the title compound 0.090 g.

N-{(E) -3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl ] Acryloyl} -3, 4-fluorobenzenesulfonamide (Compound 45)
(E) -3- [5- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] acrylic acid 0.159 g and 3,4-fluorobenzenesulfonamide 0.075 g were reacted according to the method of Example 17 to obtain 0.063 g of the title compound.

Chlorothiophene-2-sulfonic acid {(E) -3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indole- 6-yl) acryloyl] amide (Compound 46)
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.250 g And 0.107 g of thiophene-2-sulfonamide were used in the same manner as in Example 17 to obtain 0.241 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (3-fluoro-9-naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl Example of production of amide (compound 47)
(1) Preparation of (E) -3- (3-Fluoro-9-naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
Example 1 using 0.540 g of (E) -3- (3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid and 0.441 g of 1- (chloromethyl) naphthalene -The same operation as in (5) was performed to obtain 0.713 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.81 (m, 4H), 2.56 (bt, 2H), 2.69 (bt, 2H), 5.88 (s, 2H), 6.20 (d, J = 15Hz, 1H) , 6.25 (d, J = 8Hz, 1H), 7.11 (d, J = 2Hz, 11Hz, 1H), 7.29-7.35 (m, 2H), 7.60-7.66 (m, 3H), 7.82 (d, J = 8Hz , 1H), 7.98 (d, J = 8Hz, 1H), 8.19 (d, J = 8Hz, 1H).
(2) 4, 5-dichlorothiophene-2-sulfonic acid [(E) -3- (3-fluoro-9-naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Yl) acryloyl] amide (compound 47)
(E) -3- (3-Fluoro-9-naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.713 g and 4,5-dichlorothiophene-2 -The same operation as in Example 1- (6) was performed using 0.348 g of sulfonamide to obtain 0.420 g of the title compound.

5-dichlorothiophene-2-sulfonic acid [(E) -3- (3-fluoro-9-naphthalen-2-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl] amide Production Example of (Compound 48)
(1) Preparation of (E) -3- (3-Fluoro-9-naphthalen-2-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
Example 1 using 0.313 g of (E) -3- (3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid and 0.320 g of 2- (chloromethyl) naphthalene -The same operation as in (5) was performed to obtain 0.259 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.81 (m, 2H), 1.86 (m, 2H), 2.52 (bt, 2H), 2.67 (bt, 2H), 5.57 (s, 2H), 6.23 (d , J = 16Hz, 1H), 7.08-7.12 (m, 2H), 7.28 (d, J = 9Hz, 1H), 7.39 (s, 1H), 7.45-7.47 (m, 2H), 7.73 (s, 1H) , 7.85 (d, J = 9Hz, 1H), 8.02 (d, J = 15Hz, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (3-fluoro-9-naphthalen-2-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Yl) acryloyl] amide (compound 48)
(E) -3- (3-Fluoro-9-naphthalen-2-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.244 g and 4,5-dichlorothiophene-2 -The same operation as in Example 1- (6) was performed using 0.136 g of sulfonamide to obtain 0.204 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [b] thiophen-2-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1 -Ill) acryloyl] amide (Compound 49) Production Example
(1) Preparation of (E) -3- (9-benzo [b] thiophen-2-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (3-Fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid (0.998 g) and 2- (chloromethyl) benzo [b] thiophene (0.844 g) were used. In the same manner as in Example 1- (5), 1.244 g of the title compound was obtained.
¹ H-NMR (DMSO-d ₆ ) δ = 1.81 (m, 2H), 1.88 (m, 2H), 2.64 (bt, 2H), 2.75 (bt, 2H), 5.66 (s, 2H), 6.34 (d , J = 16Hz, 1H), 7.11 (s, 1H), 7.15 (d, J = 10Hz, 1H), 7.28-7.33 (m, 3H), 7.72 (d, J = 6Hz, 1H), 7.86 (d, J = 8Hz, 1H), 8.20 (d, J = 15Hz, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [b] thiophen-2-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H- Production example of carbazol-1-yl) acryloyl] amide (Compound 49)
(E) -3- (9-Benzo [b] thiophen-2-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.400 g and 4, 5- The same operation as in Example 1- (6) was carried out using 0.252 g of dichlorothiophene-2-sulfonamide to obtain 0.470 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [b] thiophen-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1 -Ill) acryloyl] amide (Compound 50) Production Example
(1) Preparation of (E) -3- (9-benzo [b] thiophen-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
(E) -3- (3-Fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.400 g and 3- (chloromethyl) benzo [b] thiophene 0.542 g were used. In the same manner as in Example 1- (5), 0.478 g of the title compound was obtained.
¹ H-NMR (DMSO-d ₆ ) δ = 1.80 (m, 4H), 2.62 (bt, 2H), 2.75 (bt, 2H), 5.60 (s, 2H), 6.23 (d, J = 16Hz, 1H) , 6.65 (s, 1H), 7.11 (d, J = 10Hz, 1H), 7.30 (d, J = 6Hz, 1H), 7.40-7.42 (m, 2H), 7.85-7.89 (m, 2H), 7.97 ( d, J = 8Hz, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [b] thiophen-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H- Carbazol-1-yl) acryloyl] amide (Compound 50)
(E) -3- (9-Benzo [b] thiophen-2-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.230 g and 4, 5- The same operation as in Example 1- (6) was performed using 0.145 g of dichlorothiophene-2-sulfonamide to obtain 0.285 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-biphenyl-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl Example of production of amide (Compound 51)
(1) Preparation of (E) -3- (9-biphenyl-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
Example 1- (E) -3- (3-Fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.400 g and 3-bromomethylbiphenyl 0.509 g The same operation as in 5) was performed to obtain 0.588 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.75 (m, 2H), 1.87 (m, 2H), 2.46 (bt, 2H), 2.66 (bt, 2H), 5.47 (s, 2H), 6.25 (d , J = 15Hz, 1H), 6.65 (d, J = 8Hz, 1H), 7.10 (dd, J = 2Hz, 10Hz, 1H), 7.26-7.58 (m, 9H), 8.04 (d, J = 15Hz, 1H ), 12.34 (bs, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-biphenyl-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Yl) acryloyl] amide (Compound 51)
(E) -3- (9-Biphenyl-3-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.294 g and 4,5-dichlorothiophene-2 -The same operation as in Example 1- (6) was performed using 0.176 g of sulfonamide to obtain 0.335 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-biphenyl-4-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl Example of production of amide (Compound 52)
(1) Preparation of (E) -3- (9-biphenyl-4-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
Example 1- (E) -3- (3-Fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.400 g and 4-bromomethylbiphenyl 0.509 g The same operation as in 5) was performed to obtain 0.501 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.83 (m, 2H), 1.87 (m, 2H), 2.66 (m, 4H), 5.47 (s, 2H), 6.27 (d, J = 15Hz, 1H) , 6.97 (d, J = 8Hz, 1H), 7.11 (dd, J = 2Hz, 10Hz, 1H), 7.28-7.45 (m, 4H), 7.58-7.63 (m, 4H), 8.02 (d, J = 15Hz , 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-biphenyl-4-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1- Yl) acryloyl] amide (Compound 52)
(E) -3- (9-Biphenyl-4-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.300 g and 4,5-dichlorothiophene-2 -The same operation as in Example 1- (6) was carried out using 0.181 g of sulfonamide to obtain 0.335 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [1, 2, 5] -thiadiazol-5-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro- 5H-Carbazol-1-yl) acryloyl] amide (Compound 53) Production Example
(1) (E) -3- (9-Benzo [1, 2, 5] -thiadiazol-5-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic Acid production
(E) -3- (3-Fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.500 g and 5-bromobenzo [1, 2, 5] thiadiazole 0.532 g In the same manner as in Example 1- (5), 0.703 g of the title compound was obtained.
¹ H-NMR (DMSO-d ₆ ) δ = 1.81 (m, 2H), 1.86 (m, 2H), 2.67 (m, 4H), 5.63 (s, 2H), 6.24 (d, J = 15Hz, 1H) , 7.07-8.08 (m, 6H).
(2) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-benzo [1, 2, 5] -thiadiazol-5-ylmethyl-3-fluoro-6, 7, 8, 9 -Tetrahydro-5H-carbazol-1-yl) acryloyl] amide (Compound 53)
(E) -3- (9-Benzo [1, 2, 5] -thiadiazol-5-ylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.350 g And 0.191 g of 4,5-dichlorothiophene-2-sulfonamide were used in the same manner as in Example 1- (6) to obtain 0.184 g of the title compound.

4, 5-dichlorothiophene-2-sulfonic acid {(E) -3- (9- (4-chloro-2-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole- 1-yl) acryloyl} amide (compound 54) production example
(1) Production of (E) -3- (4-chloro-2-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
Performed using 0.500 g of (E) -3- (3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid and 0.518 g of 4-chloro-2-fluorobenzyl chloride The same operation as in Example 1- (5) was performed to give the title compound (0.603 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.77 (m, 2H), 1.84 (m, 2H), 2.60 (m, 4H), 5.42 (s, 2H), 6.20 (d, J = 15Hz, 1H) , 6.28 (m, 1H), 7.08-7.12 (m, 2H), 7.27 (m, 1H), 7.44 (d, J = 10Hz, 1H), 7.79 (d, J = 15Hz, 1H).
(2) 4, 5-dichlorothiophene-2-sulfonic acid {(E) -3- (9- (4-chloro-2-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H -Carbazol-1-yl) acryloyl} amide (Compound 54)
(E) -3- (4-Chloro-2-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.300 g and 4,5-dichlorothiophene The same operation as in Example 1- (6) was performed using 0.191 g of -2-sulfonamide, to obtain 0.184 g of the title compound.

4, 5-dichlorothiophene-2-sulfonic acid {(E) -3- (9- (2-chloro-4-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole- 1-yl) acryloyl} amide (compound 55) production example
(1) Preparation of (E) -3- (2-chloro-4-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
Performed using 0.500 g of (E) -3- (3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid and 0.414 g of 2-chloro-4-fluorobenzyl chloride The same operation as in Example 1- (5) was performed to give the title compound (0.456 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.79 (m, 2H), 1.86 (m, 2H), 2.56 (bt, 2H), 2.64 (bt, 2H), 5.37 (s, 2H), 6.18 (m , 1H), 6.20 (d, J = 15Hz, 1H), 7.30 (d, J = 7Hz, 1H), 7.51 (dd, J = 2.7Hz, 9Hz, 1H), 7.61 (d, J = 15Hz, 1H) .
(2) 4, 5-dichlorothiophene-2-sulfonic acid {(E) -3- (9- (4-chloro-2-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H -Carbazol-1-yl) acryloyl} amide (Compound 54)
(E) -3- (4-Chloro-2-fluorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.228 g and 4,5-dichlorothiophene The same operation as in Example 1- (6) was carried out using 0.145 g of -2-sulfonamide to obtain 0.095 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-cyclohexylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl] amide ( Production Example of Compound 56)
(1) Preparation of (E) -3- (9-cyclohexyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
Example 1- (5) using 0.200 g of (E) -3- (3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid and 0164 g of bromomethylcyclohexane The title compound was obtained in the same manner as in Example 1.
¹ H-NMR (DMSO-d ₆ ) δ = 1.33 (m, 5H), 1.52-1.82 (m, 10H), 2.56 (bt, 2H), 2.67 (bt, 2H), 2.95 (d, J = 7Hz, 2H), 6.39 (d, J = 15Hz, 1H), 7.14-7.20 (m, 2H), 8.241 (d, J = 15Hz, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-cyclohexylmethyl-3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl Production of amide (compound 56)
(E) -3- (9-Cyclohexyl-3-fluoro-6,7,8,9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.140 g and 4,5-dichlorothiophene-2-sulfonamide 0.101 g was used in the same manner as in Example 1- (6) to give the title compound (0.110 g).

4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl] amide (compound 57) Production example
(1) Preparation of (E) -3- (9-Naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid
Example 1- (5) using 0.241 g of (E) -3- (6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid and 0.212 g of 1- (chloromethyl) naphthalene The title compound was obtained in the same manner as in Example 1.
¹ H-NMR (DMSO-d ₆ ) δ = 1.82 (m, 4H), 2.55 (bt, 2H), 2.73 (bt, 2H), 5.89 (s, 2H), 6.13 (d, J = 15Hz, 1H) , 6.27 (d, J = 7Hz, 1H), 7.04-7.08 (m, 1H), 7.23 (d, J = 7Hz, 1H), 7.29-7.32 (m, 1H), 7.55-7.66 (m, 3H), 7.75 (d, J = 16Hz, 1H), 7.82 (d, J = 8Hz, 1H), 7.97-8.00 (m, 1H), 8.21 (d, J = 8Hz, 1H), 11.90 (bs, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid [(E) -3- (9-naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acryloyl] Preparation of amide (compound 57)
(E) -3- (9-Naphthalen-1-ylmethyl-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.180 g and 4,5-dichlorothiophene-2-sulfonamide 0.120 g was used in the same manner as in Example 1- (6) to give the title compound (0.169 g).

4,5-dichlorothiophene-2-sulfonic acid {[(E) -9- (3-methylazulen-1-yl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acryloyl} Example of production of amide (compound 58)
(1) Preparation of (E) -3- [9- (3-Methylazulen-1-ylmethyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic acid
Example 1- (E) -3- (6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl) acrylic acid 0.400 g and 1-chloromethyl-3-methylazulene 0.340 g The same operation as in 5) was performed to obtain 0.265 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.89-1.95 (m, 4H), 2.49 (s, 3H), 2.68 (t, J = 6Hz, 2H), 2.80 (t, J = 6Hz, 2H), 5.82 (s, 2H), 6.14 (d, J = 16Hz, 1H), 6.99 (s, 1H), 7.03-7.10 (m, 3H), 7.17 (d, J = 7Hz, 1H), 7.53-7.57 (m , 2H), 7.97 (d, J = 16Hz, 1H), 8.17 (d, J = 1Hz, 1H), 8.19 (d, J = 10Hz, 1H), 11.90 (bs, 1H).
(2) 4, 5-dichlorothiophene-2-sulfonic acid {[(E) -9- (3-methylazulen-1-yl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Production of acryloyl} amide (compound 58)
(E) -3- [9- (3-Methylazulen-1-ylmethyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic acid 0.185 g and 4,5-dichlorothiophene- The same operation as in Example 1- (6) was carried out using 0.119 g of 2-sulfonamide, to obtain 0.111 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [8-fluoro-5-(3-methylazulen-1-yl) -1, 3, 4, 5-tetrahydropyrano [4 , 3-b] Indol-6-yl] acryloyl} amide (Compound 59)
(1) 3- [8-Fluoro-5- (3-methylazulen-1-yl) -1, 2, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] acrylic acid Manufacturing
(E) -3- (1, 3, 4, 5-tetrahydropyrano [4,3-b] indol-6-yl) acrylic acid 0.400 g and 1-chloromethyl-3-methylazulene 0.339 g were used. In the same manner as in Example 1- (5), 0.219 g of the title compound was obtained.
¹ H-NMR (DMSO-d ₆ ) δ = 2.43 (s, 3H), 2.72 (bt, 2H), 3.94 (bt, 2H), 4.80 (s, 2H), 5.85 (s, 2H), 6.24 (d , J = 15Hz, 1H), 6.83 (s, 1H), 7.08-7.13 (m, 3H), 7.31 (dd, J = 3Hz, 9Hz, 1H), 7.62 (t, J = 10Hz, 1H), 7.97 ( d, J = 15Hz, 1H), 8.21 (d, J = 9Hz, 1H), 8.37 (d, J = 9Hz, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid {(E) -3- [8-fluoro-5-(3-methylazulen-1-yl) -1, 3, 4, 5-tetrahydropyra Of [4,3-b] indol-6-yl] acryloyl} amide (Compound 59)
3- [5- (3-Methylazulen-1-yl) -1, 2, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] acrylic acid 0.200 g and 4, 5-dichloro The same operation as in Example 1- (6) was carried out using 0.123 g of thiophene-2-sulfonamide, to obtain 0.215 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionyl} Example of production of amide (Compound 60)
(1) Preparation of 3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionic acid
(E) -3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic acid 0.350 g tetrahydrofuran 3.5 mL and methanol 0.035 g of 5% palladium carbon was added to the 3.5 mL solution, and the mixture was stirred at room temperature for 30 minutes in a hydrogen gas atmosphere. The reaction mixture was filtered, and the filtrate was evaporated under reduced pressure to give the title compound (0.301 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.78 (m, 2H), 1.83 (m, 2H), 2.46 (t, J = 7Hz, 2H), 2.55 (bt, 2H), 2.62 (bt, 2H) , 2.84 (t, J = 7Hz, 2H), 5.43 (s, 2H), 5.95 (d, J = 8Hz, 1H), 6.70 (dd, J = 3Hz, 11Hz, 1H), 7.06 (dd, J = 2Hz , 9Hz, 1H), 7.27 (dd, J = 2Hz, 9Hz, 2H), 7.69 (d, J = 2Hz, 1H), 12.16 (s, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid {3- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Production of propionyl} amide (compound 60)
3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionic acid 0.290 g and 4, 5-dichlorothiophene-2- The same operation as in Example 1- (6) was performed using 0.176 g of sulfonamide to obtain 0.230 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionyl} amide (Compound 61 ) Production example
(1) Preparation of 3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionic acid
(E) -3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic acid 0.370 g in tetrahydrofuran 3.5 mL and methanol 3.5 mL 0.037 g of 5% palladium carbon was added, and the mixture was stirred at room temperature for 2 hours and 30 minutes in a hydrogen gas atmosphere. The reaction mixture was filtered, and the filtrate was evaporated under reduced pressure to give the title compound (0.350 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.94 (m, 4H), 2.45 (t, J = 6Hz, 2H), 2.58 (bt, 2H), 2.76 (bt, 2H), 2.84 (t, J = 6Hz, 2H), 5.36 (s, 2H), 6.30 (d, J = 8Hz, 1H), 7.04-7.11 (m, 3H), 7.20 (d, J = 2Hz, 2H), 7.55 (d, J = 8Hz , 1H), 12.16 (s, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid {3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionyl} amide Production of (Compound 61)
3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionic acid 0.332 g and 4,5-dichlorothiophene-2-sulfonamide 0.210 g Was used in the same manner as in Example 1- (6) to give the title compound (0.050 g).

4,5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indole- 6-yl] propionyl} amide (Compound 62) Production Example
(1) Preparation of 3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 2, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] propionic acid
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1, 2, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] propionic acid 0.300 g Was used in the same manner as in Example 60- (1) to give the title compound (0.222 g).
¹ H-NMR (DMSO-d ₆ ) δ = 2.46 (t, J = 8Hz, 2H), 2.69 (t, J = 5Hz, 2H), 2.85 (t, J = 8Hz, 2H), 2.95 (t, J = 5Hz, 2H), 4.80 (s, 2H), 4.77 (s, 2H), 5.47 (s, 2H), 5.97 (d, J = 8Hz, 1H), 6.74 (dd, J = 2hz, 11Hz, 1H) , 7.08 (dd, J = 3Hz, 9Hz, 1H), 7.29 (dd, J = 2Hz, 9Hz, 1H), 7.70 (d, J = 2Hz, 1H), 12.187 (bs, 1H).
(2) 4, 5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b ] Indol-6-yl] Production of propionyl} amide (Compound 62)
3- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 2, 4, 5-tetrahydropyrano [4,3-b] indol-6-yl] propionic acid 0.175 g and 4, 5 -The same operation as in Example 1- (6) was performed using 0.106 g of dichlorothiophene-2-sulfonamide to obtain 0.176 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] Indol-4-yl] propionyl} amide (Compound 63) Production Example
(1) 3- [9- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] propionic acid Manufacturing
(E) -3- [5- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] acrylic acid The same operation as in Example 60- (1) was performed using 0.300 g, and 0.280 g of the title compound was obtained.
¹ H-NMR (DMSO-d ₆ ) δ = 1.29 (m, 2H), 1.38 (m, 2H), 1.49 (m, 2H), 1.60 (m, 2H), 2.42-2.50 (m, 4H), 2.73 -2.84 (m, 4H), 5.47 (s, 2H), 5.97 (d, J = 8Hz, 1H), 6.66 (dd, J = 3Hz, 11Hz, 1H), 7.12 (dd, J = 2Hz, 9Hz, 1H ), 7.25 (dd, J = 2Hz, 9Hz, 2H), 7.66 (d, J = 2Hz, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta Preparation of [b] Indol-4-yl] propionyl} amide (Compound 63)
3- [9- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] propionic acid 0.280 g and 4 , 5-dichlorothiophene-2-sulfonamide was used in the same manner as in Example 1- (6) to give the title compound (0.304 g).

4,5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole-4- [Ill] propionyl} amide (Compound 64)
(1) Preparation of 3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] propionic acid
(E) -3- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] acryloic acid 0.355 g was used Then, the same operation as in Example 60- (1) was carried out to obtain 0.338 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.30 (m, 2H), 1.38 (m, 2H), 1.56 (m, 2H), 1.62 (m, 2H), 2.44 (m, 4H), 2.77-2.83 (m, 4H), 5.48 (s, 2H), 5.95 (d, J = 8Hz, 1H), 6.81 (s, 1H), 6.92 (t, J = 7Hz, 1H), 7.23 (d, 9Hz, 1H) , 7.35 (d, 9Hz, 2H), 7.66 (s, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid {3- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole -4-yl] propionyl} amide (Compound 64)
3- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] propionic acid 0.338 g and 4, 5-dichloro The same operation as in Example 1- (6) was carried out using 0.201 g of thiophene-2-sulfonamide to give the title compound (0.170 g).

4,5-dichlorothiophene-2-sulfonic acid {(E) -4- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1- [Il] bute-3-enoyl} amide (Compound 65)
(1) (E) -4- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] bute-3-enoyl acid Manufacturing of
8-Bromo-9- (2,4-dichlorobenzyl) -6-fluoro-2,3,4,9-tetrahydro-1H-carbazole (1.000 g) in acetonitrile (10.0 mL) solution with triethylamine (2.1 mL) and 3-butenoic acid (0.423 g) Tri- (o-tolyl) phosphine (0.112 g) and palladium (II) acetate (0.028 g) were added at room temperature, and the mixture was heated to reflux for 2 hours. After the reaction solution was cooled to room temperature, water was added. A 10% aqueous hydrochloric acid solution was added to adjust the pH to about 2, and the mixture was extracted with ethyl acetate. The extract was washed successively with water, saturated aqueous sodium hydrogen carbonate solution, 10% aqueous hydrochloric acid solution, water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. The obtained residue was washed with n-hexane and dried to give the title compound (0.899 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.79-1.87 (m, 4H), 2.75 (bt, 2H), 2.67 (bt, 2H), 3.02-3.04 (m, 2H), 5.43 (s, 2H) , 5.84-5.88 (m, 1H), 6.12 (d, J = 8Hz, 1H), 6.58 (d, J = 16Hz, 1H), 6.91-7.00 (m, 2H), 7.28 (dd, J = 2Hz, 8Hz , 1H), 7.37 (dd, J = 1Hz, 8Hz, 1H), 7.70 (d, J = 2Hz, 1H), 12.30 (s, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid {(E) -4- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole -1-yl] bute-3-enoyl} amide (compound 65)
(E) -4- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] bute-3-enoyl acid
The same operation as in Example 1- (6) was carried out using 0.246 g and 4,52-dichlorothiophene-2-sulfonamide 0.152 g to obtain the title compound 0.135 g.

4,5-dichlorothiophene-2-sulfonic acid {(E) -4- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3- b] Indol-6-yl] bute-3-enoyl} amide (Compound 66)
(1) (E) -4- [5- (2,4-Dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] Production of te-3-enoyl acid
Example 65- () using 0.100 g of 6-bromo-5- (2,4-dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indole The same operation as in 1) was performed to obtain 0.079 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 2.70 (bt, 2H), 3.02 (m, 2H), 3.95 (t, J = 5Hz, 2H), 4.77 (s, 2H), 5.45 (s, 2H) , 5.93 (dt, J = 7Hz, 15Hz, 1H), 6.12 (d, J = 9Hz, 1H), 6.56 (d, J = 15Hz, 2H), 6.77 (dd, J = 3Hz, 11Hz, 1H), 7.15 (dd, J = 2Hz, 9Hz, 1H), 7.28 (dd, J = 2Hz, 8Hz, 1H), 7.69 (d, J = 2Hz, 1H), 12.29 (s, 1H).
(2) 4,5-dichlorothiophene-2-sulfonic acid {(E) -4- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4 , 3-b] Indol-6-yl] bute-3-enoyl} amide (Compound 66)
(E) -4- [5- (2,4-Dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] bute-3 -The same operation as in Example 1- (6) was performed using 0.079 g of enoyl acid and 0.046 g of 4,5-dichlorothiophene-2-sulfonamide to obtain 0.093 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {4- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] butyryl} Production example of amide (compound 67)
4,5-dichlorothiophene-2-sulfonic acid {(E) -4- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1- To a solution of 0.203 g [Il] bute-3-enoyl} amide in tetrahydrofuran (2.0 mL) and methanol (2.0 mL) was added 5% palladium carbon (0.021 g), and the mixture was stirred at room temperature for 2 hours in a hydrogen gas atmosphere. After filtration of the reaction solution, the filtrate was evaporated under reduced pressure, and 0.185 g of the title compound was separated from the resulting residue by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (DMSO-d ₆ ) δ = 1.66-1.82 (m, 4H), 2.27 (t, J = 7Hz, 2H), 2.52 (m, 4H), 2.64 (bt, 2H), 5.38 (s, 2H), 5.88 (d, J = 8Hz, 1H), 6.69 (d, J = 7Hz, 1H), 6.90 (t, J = 7Hz, 1H), 7.22 (d, J = 8Hz, 1H), 7.28 (d , J = 7Hz, 1H), 7.65 (d, J = 2Hz, 1H), 7.83 (s, 1H), 12.60 (s, 1H).

4,5-dichlorothiophene-2-sulfonic acid {2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yloxy] acetyl} Production Example of Amide (Compound 68)
(1) Preparation of 9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1-boronic acid
2-Bromo-9- (2,4-dichlorobenzyl) -6-fluoro-2,3,4,9-tetrahydro-1H-carbazole 2.76 M n-butyllithium at -78 ° C in a solution of 0.600 g of tetrahydrofuran After dropwise addition of 0.56 mL of / n-hexane solution, the mixture was stirred at the same temperature for 50 minutes. After dropwise addition of 0.36 mL of triisopropyl borate to the reaction solution at the same temperature, the mixture was stirred at room temperature for 20 hours and 37 minutes. To the reaction mixture was added 3.0 mL of 0.5N hydrochloric acid at room temperature, and the mixture was stirred at the same temperature for 20 minutes. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.042 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 1.88 (m, 4H), 2.52 (bt, 2H), 2.71 (bt, 2H), 4.75 (s, 2H), 5.33 (s, 1H), 5.99 (d, J = 8Hz, 1H), 6.91-7.10 (m, 1H), 7.11 (m, 1H), 7.37-7.45 (m, 3H).
(2) Preparation of 9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-ol
30% hydrogen peroxide at room temperature in a suspension of 0.040 g of 9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazole-1-boronic acid at room temperature 0.012 g of an aqueous solution was added and stirred for 18 hours and 45 minutes. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.020 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 1.86 (m, 4H), 2.50 (bt, 2H), 2.66 (bt, 2H), 5.01 (s, 1H), 5.34 (s, 2H), 6.18 (d, J = 9Hz, 1H), 6.24 (dd, J = 2Hz, 10Hz, 1H), 6.73 (dd, J = 7Hz, 9Hz, 1H), 7.02 (dd, J = 2Hz, 8Hz, 1H), 7.30 (d, J = 2Hz, 1H).

(3) Preparation of [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yloxy] acetic acid ethyl ester
To a solution of 0.030 g of 9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-ol in 0.5 mL of N, N-dimethylformamide at room temperature, potassium carbonate 0.014 g and 0.011 mL of bromoacetic acid ethyl ester were added, and the mixture was stirred for 3 hours and 50 minutes. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.020 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 1.27 (t, J = 7Hz, 3H), 1.85 (m, 4H), 2.48 (bt, 2H), 2.65 (bt, 2H), 3.85 (s, 2H), 4.25 (q, J = 7Hz, 2H), 4.51 (s, 2H), 6.17 (d, J = 9Hz, 1H), 6.25 (d, J = 10Hz, 1H), 6.79 (d, J = 9Hz, 1H), 7.00 (d, J = 9Hz, 1H), 7.37 (d, J = 2Hz, 1H).
(4) Preparation of [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yloxy] acetic acid
[9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yloxy] acetic acid ethyl ester 0.020 g in tetrahydrofuran 0.15 mL and methanol 0.15 mL in room temperature After adding 0.2 mL of 10% aqueous sodium hydroxide solution, the mixture was stirred at the same temperature for 4 hours and 40 minutes. After the reaction solution was distilled off under reduced pressure, a 10% aqueous hydrochloric acid solution was added to the residual aqueous layer to adjust the pH to about 2. The mixture was extracted with ethyl acetate, and the extract was dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.011 g of the title compound was separated by silica gel column chromatography (chloroform-methanol).
¹ H-NMR (CDCl ₃ ) δ = 1.76 (m, 4H), 2.35 (bt, 2H), 2.56 (bt, 2H), 4.19 (s, 2H), 5.48 (s, 2H), 6.07 (m, 1H ), 6.17 (m, 1H), 6.67 (m, 1H), 6.88 (m, 1H), 7.20 (s, 1H).
(5) 4,5-dichlorothiophene-2-sulfonic acid {2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yloxy ] Acetyl} amide (compound 68) production
[9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yloxy] acetic acid 0.011 g and 4,5-dichlorothiophene-2-sulfonamide 0.007 g was used in the same manner as in Example 1- (6) to give the title compound 0.009 g.

4,5-dichlorothiophene-2-sulfonic acid {2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropane Production example of carbonyl} amide (compound 69)
(1) Preparation of (E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic acid methyl ester
8-Bromo-9- (2,4-dichlorobenzyl) -6-fluoro-2,3,4,9-tetrahydro-1H-carbazole -o-Tolylphosphine 0.321 g palladium (II) acetate 0.079 g was added, and the mixture was heated to reflux for 20 hours and 31 minutes. The reaction solution was allowed to cool, poured into a saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 2.354 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 1.84-1.91 (m, 4H), 2.57 (t, J = 6Hz, 1H), 2.70 (t, J = 6Hz, 5H), 3.72 (s, 3H), 5.34 ( s, 2H), 6.18 (d, J = 16Hz, 1H), 6.26 (d, J = 9Hz, 1H), 6.93 (dd, J = 2Hz, 10Hz, 1H), 7.07 (dd, J = 2Hz, 9Hz, 1H), 7.18 (dd, J = 2Hz, 9Hz, 1H), 7.48 (d, J = 2Hz, 1H), 7.73 (d, J = 16Hz, 1H).
(2) Preparation of 2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid methyl ester Sodium hydride To 0.160 g, 6.0 mL of dimethyl sulfoxide was added and stirred at about 50 ° C. for 1 hour. After cooling the reaction solution to room temperature, 0.993 g of trimethylsulfonium iodide was added and stirred for 31 minutes. (E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic acid methyl ester 0.650 g of dimethyl at the same temperature A sulfoxide 1.0 mL solution was added, and the mixture was stirred at about 45 ° C. for 2 hours. The reaction solution was cooled to room temperature and then poured into a saturated aqueous ammonium chloride solution. After extraction with toluene, the extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.413 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 1.24-1.31 (m, 1H), 1.38-1.43 (m, 1H), 1.83-1.88 (m, 5H), 2.49 (t, J = 6Hz, 2H), 2.61- 2.65 (m, 1H), 2.68 (t, J = 6Hz, 2H), 3.65 (s, 3H), 5.52 (d, J = 19Hz, 1H), 5.59 (d, J = 19Hz, 1H), 5.98 (d , J = 9Hz, 1H), 6.60 (dd, J = 2Hz, 11Hz, 1H), 7.00-7.06 (m, 2H), 7.40 (d, J = 2Hz, 1H).

(3) Preparation of 2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid
2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid methyl ester 0.390 g of tetrahydrofuran 4.0 mL and methanol To the 4.0 mL solution, 2.0 mL of a 10% aqueous sodium hydroxide solution was added at room temperature, and the mixture was stirred at the same temperature for 15 hours and 21 minutes. After the reaction solution was distilled off under reduced pressure, a 10% aqueous hydrochloric acid solution was added to the residual aqueous layer to adjust the pH to about 2. The mixture was extracted with ethyl acetate, and the extract was dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure to obtain 0.315 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.17-1.19 (m, 1H), 1.32-1.34 (m, 1H), 1.74-1.80 (m, 5H), 2.44 (bt, 2H), 2.61 (t, J = 6Hz, 2H), 5.57 (s, 2H), 5.92 (d, J = 9Hz, 1H), 6.64 (dd, J = 2Hz, 11Hz, 1H), 7.11 (dd, J = 2Hz, 9Hz, 1H) , 7.26 (dd, J = 2Hz, 8Hz, 1H), 7.64 (d, J = 7Hz, 1H), 12.30 (bs, 1H).
(4) 4,5-dichlorothiophene-2-sulfonic acid {2- [9- (2,4-dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl ] Production of cyclopropanecarbonyl} amide (Compound 69)
2- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid 0.300 g and 4,5-dichlorothiophene- The same operation as in Example 1- (6) was carried out using 0.177 g of 2-sulfonamide, to obtain 0.258 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarbonyl} amide ( Example of production of compound 70)
(1) Preparation of 2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid methyl ester
Example 69 Using 0.200 g of (E) -3- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] acrylic acid methyl ester -The same operation as in (1) was performed to obtain 0.161 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.30-1.35 (m, 1H), 1.38-1.42 (m, 1H), 1.83-1.90 (m, 5H), 2.49 (bt, 3H), 2.65-2.73 (m, 1H), 2.75 (bt, 2H), 3.65 (s, 3H), 5.56 (d, J = 19Hz, 1H), 5.58 (d, J = 19Hz, 1H), 6.02 (d, J = 8Hz, 1H), 6.86 (d, J = 8Hz, 1H), 6.98-7.03 (m, 2H), 7.31-7.43 (m, 2H).
(2) Preparation of 2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid
Example 69- () using 0.250 g of 2- [9- (2,4-dichlorobenzyl) -6,7,8,9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid methyl ester The same operation as in 2) was performed to obtain 0.207 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.16-1.22 (m, 1H), 1.26-1.31 (m, 1H), 1.72-1.82 (m, 5H), 2.42-2.57 (m, 3H), 2.67 ( bt, 1H), 2.67 (bt, 2H), 5.61 (s, 2H), 5.92 (d, J = 9Hz, 1H), 6.81 (d, J = 7Hz, 1H), 6.94 (t, J = 8Hz, 1H ), 7.26 (dd, J = 2Hz, 8Hz, 1H), 7.36 (d, J = 7Hz, 1H), 7.65 (d, J = 2Hz, 1H), 12.26 (bs, 1H).
(3) 4,5-dichlorothiophene-2-sulfonic acid {2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarbonyl } Production of amide (compound 70)
2- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid 0.197 g and 4,5-dichlorothiophene-2-sulfonamide The same operation as in Example 1- (6) was performed using 0.121 g, to obtain 0.172 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indole- 6-yl] cyclopropanecarbonyl} amide (Compound 71) Production Example
(1) Methyl 2- [5- (2,4-dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl] cyclopropanecarboxylate Esters production
(E) -3- [5- (2,4-Dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl] acrylic acid methyl ester The same operation as in Example 69- (1) was performed using 0.400 g, to obtain 0.373 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.28-1.32 (m, 1H), 1.40-1.44 (m, 1H), 1.86-1.89 (m, 1H), 2.61-2.64 (m, 3H), 3.66 (s, 3H), 4.03 (t, J = 5Hz, 2H), 4.87 (s, 1H), 5.56 (d, J = 18Hz, 1H), 5.59 (d, J = 18Hz, 1H), 6.01 (d, J = 8Hz , 1H), 6.96 (dd, J = 2Hz, 9Hz, 1H), 7.03 (dd, J = 2Hz, 8Hz, 1H), 7.42 (d, J = 2Hz, 1H).

(2) Preparation of 2- [9- (2,4-dichlorobenzyl) -8-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid
Performed using 0.370 g of 2- [9- (2,4-dichlorobenzyl) -8-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid methyl ester The same operation as in Example 69- (2) was performed to give the title compound (0.299 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.18-1.20 (m, 1H), 1.33-1.34 (m, 1H), 1.75-1.78 (m, 1H), 2.42-2.63 (m, 3H), 3.90 ( t, J = 5Hz, 2H), 4.75 (s, 2H), 5.91 (d, J = 19Hz, 1H), 5.93 (d, J = 19Hz, 1H), 5.94 (d, J = 8Hz, 1H), 6.67 (dd, J = 2Hz, 11Hz, 1H), 7.13 (dd, J = 2Hz, 9Hz, 1H), 7.26 (d, J = 2Hz, 8Hz, 1H), 7.64 (d, J = 2Hz, 1H).
(3) 4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b ] Preparation of indol-6-yl] cyclopropanecarbonyl} amide (compound 71)
2- [9- (2,4-Dichlorobenzyl) -8-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid 0.230 g and 4,5-dichlorothiophene- The same operation as in Example 1- (6) was carried out using 0.135 g of 2-sulfonamide, to obtain 0.220 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] Indol-4-yl] cyclopropanecarbonyl} amide (Compound 72) Production Example
(1) 2- [5- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] cyclopropanecarboxylic acid Production of acid methyl ester
(E) -3- [5- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] acrylic acid The same operation as in Example 69- (1) was carried out using 0.400 g of the methyl ester to obtain 0.223 g of the title compound.
¹ H-NMR (CDCl ₃ ) δ = 1.24-1.44 (m, 6H), 1.55-1.58 (m, 2H), 1.66-1.69 (m, 2H), 1.86-1.91 (m, 1H), 2.61-2.66 ( m, 1H), 2.69 (t, J = 6Hz, 2H), 2.82 (t, J = 6Hz, 2H), 3.65 (s, 3H), 5.60 (d, J = 19Hz, 1H), 5.63 (d, J = 19Hz, 1H), 6.03 (d, J = 8Hz, 1H), 6.59 (dd, J = 2Hz, 10Hz, 1H), 7.01 (dd, J = 2Hz, 8Hz, 2H), 7.09 (dd, J = 2Hz , 9Hz, 1H), 7.41 (d, J = 2Hz, 1H).
(2) 2- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] cyclopropanecarboxylic acid Acid production
2- [5- (2,4-Dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] cyclopropanecarboxylic acid methyl ester The same operation as in Example 69- (2) was performed using 0.210 g, to obtain the title compound 0.188 g.
¹ H-NMR (DMSO-d ₆ ) δ = 1.15-1.61 (m, 10H), 1.76-1.80 (m, 1H), 2.40-2.50 (m, 1H), 2.71 (t, J = 6Hz, 2H), 2.80 (t,, J = 6Hz, 2H), 5.63 (d, J = 19Hz, 1H), 5.65 (d, J = 19Hz, 1H), 5.97 (d, J = 8Hz, 1H), 6.62 (dd, J = 2Hz, 11Hz, 1H), 7.17-7.27 (m, 2H), 7.64 (d, J = 2Hz, 1H), 12.20 (bs, 1H).
(3) 4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta Preparation of [b] Indol-4-yl] cyclopropanecarbonyl} amide (Compound 72)
2- [5- (2,4-dichlorobenzyl) -2-fluoro-6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] cyclopropanecarboxylic acid 0.180 g And 0.15-g of 4,5-dichlorothiophene-2-sulfonamide were used in the same manner as in Example 1- (6) to obtain 0.159 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole-4- [Ill] cyclopropanecarbonyl} amide (Compound 73)
(1) 2- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] cyclopropanecarboxylic acid methyl ester Manufacturing
(E) -3- [5- (2,4-Dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] acrylic acid methyl ester 0.300 g Was used in the same manner as in Example 69- (1) to give the title compound (0.145 g).
¹ H-NMR (CDCl ₃ ) δ = 1.37-1.41 (m, 6H), 1.50 (m, 2H), 1.71 (m, 2H), 1.90 (m, 1H), 2.69 (t, J = 6Hz, 1H) , 2.88 (t, J = 6Hz, 2H), 3.64 (s, 3H), 5.65 (d, J = 19Hz, 1H), 5.67 (d, J = 19Hz, 1H), 6.06 (d, J = 8Hz, 1H ), 6.85 (d, J = 10Hz, 1H), 6.97-7.03 (m, 2H), 7.40 (s, 1H), 7.47 (d, J = 8Hz, 1H).
(2) Preparation of 2- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] cyclopropanecarboxylic acid
Using 0.145 g of 2- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] cyclopropanecarboxylic acid methyl ester Then, the same operation as in Example 69- (2) was performed to obtain 0.138 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.29 (m, 2H), 1.37 (m, 2H), 1.46 (m, 1H), 1.61 (m, 2H), 1.73 (m, 1H), 2.70 (m , 2H), 2.82 (m, 2H), 5.66 (s, 2H), 5.95 (d, J = 8Hz, 1H), 6.78 (d, J = 7Hz, 1H), 6.93 (t, J = 7Hz, 1H) , 7.22 (d, J = 8Hz, 1H), 7.41 (d, J = 8Hz, 1H), 7.63 (s, 1H).
(3) 4,5-dichlorothiophene-2-sulfonic acid {2- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indole -4-yl] cyclopropanecarbonyl} amide (compound 73)
2- [5- (2,4-dichlorobenzyl) -6, 7, 8, 9, 10, 11-hexahydro-5H-cycloocta [b] indol-4-yl] cyclopropanecarboxylic acid 0.117 g and 4, 5 The same operation as in Example 1- (6) was carried out using 0.068 g of -dichlorothiophene-2-sulfonamide to obtain 0.108 g of the title compound.

4,5-dichlorothiophene-2-sulfonic acid {(Z) -2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopent- Production example of 1-enecarbonyl} amide (compound 74)
(1) Preparation of 9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazole-1-boronic acid
2-Bromo-9- (2,4-dichlorobenzyl) -2,3,4,9-tetrahydro-1H-carbazole in a solution of 1.000 g of tetrahydrofuran in 5.0 mL of tetrahydrofuran at -78 ° C with 2.76 M n-butyllithium / n-hexane After 0.98 mL of the solution was added dropwise, the mixture was stirred at the same temperature for 51 minutes. After dropwise addition of 0.64 mL of triisopropyl borate to the reaction solution at the same temperature, the mixture was stirred at room temperature for 1 hour and 51 minutes. To the reaction mixture was added 5.0 mL of 0.5N hydrochloric acid at room temperature, and the mixture was stirred at the same temperature for 1 hour and 7 minutes. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.483 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
(2) Preparation of 2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopent-1-enecarboxylic acid ethyl ester
9- (2,4-Dichlorobenzyl) -6,7,8,9-tetrahydro-5H-carbazole-1-boronic acid 0.483 g and 2-trifluoromethanesulfonyloxycyclopent-1-enecarboxylic acid ethyl ester 0.327 g After adding 0.75 mL of 2M aqueous sodium carbonate solution and 0.149 g of tetrakis (triphenylphosphine) palladium (0) to 6.5 mL of 1,2-dimethoxyethane, the mixture was heated to reflux for 2 hours and 3 minutes. After the reaction solution was cooled to room temperature, a saturated ammonium chloride transition solution was added. The mixture was extracted with ethyl acetate, and the extract was washed successively with water and saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.533 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 0.82 (t, J = 7Hz, 3H), 1.50-1.54 (m, 1H), 1.72-1.95 (m, 5H), 2.28 (m, 1H), 2.53 (m, 2H), 2.62-2.78 (m, 5H), 3.76 (q, J = 7Hz, 2H), 5.13 (d, J = 18Hz, 1H), 5.33 (d, J = 18Hz, 1H), 5.97 (d, J = 8Hz, 1H), 6.71 (dd, J = 1Hz, 8Hz, 1H), 6.95 (dd, J = 2Hz, 10Hz, 1H), 7.05 (dd, J = 7Hz, 7Hz, 1H), 7.36 (d, J = 2Hz, 1H), 7.44 (dd, J = 1Hz, 8Hz, 1H).

(3) Preparation of 2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopent-1-enecarboxylic acid
Example using 0.150 g of 2- [9- (2,4-dichlorobenzyl) -6,7,8,9-tetrahydro-5H-carbazol-1-yl] cyclopent-1-enecarboxylic acid ethyl ester The same operation as in 1- (5) was performed to give the title compound (0.133 g).
¹ H-NMR (DMSO-d ₆ ) δ = 1.40-1.43 (m, 1H), 1.78-1.89 (m, 5H), 2.43-2.66 (m, 8H), 5.10 (d, J = 19Hz, 1H), 5.40 (d, J = 19Hz, 1H), 5.95 (d, J = 8Hz, 2H), 6.62 (dd, J = 1Hz, 7Hz, 1H), 6.95 (t, J = 7Hz, 1H), 7.18 (d, J = 8Hz, 1H), 7.33 (dd, J = 1Hz, 7Hz, 1H), 7.62 (d, J = 2Hz, 1H).
(4) 4,5-dichlorothiophene-2-sulfonic acid {(Z) -2- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl Preparation of cyclopent-1-enecarbonyl} amide (compound 74)
2- [9- (2,4-Dichlorobenzyl) -6,7,8,9-tetrahydro-5H-carbazol-1-yl] cyclopent-1-enecarboxylic acid 0.133 g and 4,5-dichlorothiophene-2 -Using sulfonamide 0.082g, it carried out similarly to Example 1- (6), and obtained the title compound 0.139g.
(5) Preparation of 2-trifluoromethanesulfonyloxycyclopent-1-enecarboxylic acid ethyl ester 2-oxocyclopentanecarboxylic acid in a suspension of 2.286 g (63% NaH) of sodium hydride in 100.0 mL of tetrahydrofuran under ice-cooling After 7.3 mL of ethyl ester was added dropwise and stirred for 14 minutes at the same temperature, 21.435 g of N-phenyl-bis (trifluoromethanesulfonimide) was added and stirred for 16 hours and 20 minutes at room temperature. The reaction solution was poured into a saturated aqueous solution of sodium bicarbonate and extracted with ether. The extract was washed successively with water and saturated brine, and then dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 12.787 g of the title compound was separated by silica gel column chromatography (ether-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 1.30-1.34 (t, J = 7Hz, 3H), 1.97-2.05 (m, 2H), 2.69-2.74 (m, 4H), 4.26 (q, J = 7Hz, 2H ).

4, 5-dichlorothiophene-2-sulfonic acid {4- [9- (2, 4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] benzoylamide (Compound 75) Example of manufacturing
(1) Preparation of 4- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] benzoic acid methyl ester
A solution of 0.500 g of 8-bromo-9- (2,4-dichlorobenzyl) -2,3,4,9-tetrahydro-1H-carbazole and 0.265 g of 4-methoxycarbonylphenylboronic acid in 5.0 mL of 1,2-dimethoxyethane To the mixture, 1.0 mL of 2M aqueous sodium carbonate solution and 0.142 g of tetrakis (triphenylphosphine) palladium (0) were added, followed by heating under reflux for 13 hours and 34 minutes. After the reaction solution was cooled to room temperature, a saturated ammonium chloride transition solution was added. The mixture was extracted with ethyl acetate, and the extract was washed successively with water and saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled off under reduced pressure. From the obtained residue, 0.533 g of the title compound was separated by silica gel column chromatography (ethyl acetate-n-hexane).
¹ H-NMR (CDCl ₃ ) δ = 1.90 (m, 4H), 2.50 (t, J = 5Hz, 1H), 2.81 (t, J = 5Hz, 2H), 3.95 (s, 3H), 4.75 (s, 2H), 5.93 (d, J = 8Hz, 1H), 6.85 (dd, J = 1Hz, 7Hz, 1H), 6.97 (dd, J = 2Hz, 8Hz, 1H), 7.08-7.14 (m, 3H), 7.20 (d, J = 2Hz, 1H), 7.56 (dd, J = 1Hz, 7Hz, 1H), 7.83 (d, J = 9Hz, 2H).
(2) Preparation of 4- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] benzoic acid
Example 1- (5) using 0.500 g of 4- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] benzoic acid methyl ester The same operation as in Example 1 was performed to obtain 0.403 g of the title compound.
¹ H-NMR (DMSO-d ₆ ) δ = 1.78-1.83 (m, 4H), 2.47 (bt, 2H), 2.74 (bt, 2H), 4.80 (s, 2H), 5.84 (d, J = 8Hz, 1H), 6.77 (d, J = 7Hz, 1H), 7.05-7.09 (m, 4H), 7.22 (dd, J = 1Hz, 8Hz, 1H), 7.42 (d, J = 2Hz, 1H), 7.51 (d , J = 8Hz, 1H), 7.74 (d, J = 8Hz, 1H), 12.93 (bs, 1H).
(3) 4,5-dichlorothiophene-2-sulfonic acid {4- [9- (2,4-dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] benzoylamide ( Production of compound 75)
4- [9- (2,4-Dichlorobenzyl) -6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] benzoic acid 0.403 g and 4, 5-dichlorothiophene-2-sulfonamide 0.228 g Was used in the same manner as in Example 1- (6) to give the title compound (0.233 g).

N- {3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionyl} -3, 4-difluorobenzenesulfonamide Production Example of (Compound 76)
3- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] propionic acid 0.255 g and 3, 4-difluorobenzenesulfonamide 0.129 was used in the same manner as in Example 30 to obtain the title compound (0.166 g).

N- {2- [9- (2,4-Dichlorobenzyl) -3-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarbonyl} -3, 4-difluorobenzene Production example of sulfonamide (Compound 77)
2- [9- (2,4-Dichlorobenzyl) -8-fluoro-6, 7, 8, 9-tetrahydro-5H-carbazol-1-yl] cyclopropanecarboxylic acid 0.435 g and 3, 4-difluorobenzenesulfone The same operation as in Example 30 was performed using 0.214 g of the amide, to obtain 0.333 g of the title compound.

N- {2- [5- (2,4-dichlorobenzyl) -8-fluoro-1, 3, 4, 5-tetrahydropyrano [4, 3-b] indol-6-yl] cyclopropanecarbonyl}- 3, 4-difluorobenzenesulfonamide (Compound 78)
2- [5- (2,4-dichlorobenzyl) -8-fluoro-1,3,4,5-tetrahydropyrano [4,3-b] indol-6-yl] cyclopropanecarboxylic acid 0.140 g and 3 , 4-difluorobenzenesulfonamide 0.068 g was used in the same manner as in Example 30 to obtain 0.069 g of the title compound.
The chemical structural formulas, 1H-NMR data and MS data of the compounds 1 to 78 obtained in Examples 1 to 78 are shown in Tables 1 to 16.

Claims (13)

Formula (I):

[Wherein, R ¹ and R ² are a hydrogen atom, a monocyclic or bicyclic aromatic ring optionally having a substituent, a monocyclic or bicyclic heterocyclic ring optionally having a substituent, and a branch. A lower alkyl group which may form a ring, a lower alkyl group to which a monocyclic or bicyclic aromatic ring or heterocyclic ring which may have a substituent is bonded, a lower alkoxy group A lower alkyl group having an allyloxy group which may have a substituent, a lower alkyl group having a lower haloalkyloxy group, a lower alkyl group having an amino group which may have a substituent, lower alkylthio Group having lower alkyl group, lower alkyl group having lower alkylsulfonyl group, lower alkyl group having carboxyl group, lower alkyl group having lower alkoxycarbonyl group, lower alkyl group having sulfonamide group Kill group, lower alkyl group having hydroxyl group, lower alkyl group having sulfonic acid, lower alkyl group having cyano group, lower alkyl group having nitro group, lower haloalkyl group, lower alkoxy group (1-5 carbon atoms), lower Haloalkoxy group (1-5 carbon atoms), lower alkoxycarbonyl group (1-5 carbon atoms), halogen atom, hydroxyl group, cyano group, carboxyl group, nitro group, amino group which may be substituted, carbamoyl group, aminosulfonyl Group, lower alkanoyl group (1-5 carbon atoms), optionally substituted allylcarbonyl group, lower alkoxycarbonyl group (1-5 carbon atoms), lower alkylthio group (1-5 carbon atoms), optionally substituted. Allylthio group, lower alkylsulfonyl group (1-5 carbon atoms), optionally substituted allylsulfonyl group, lower alkylsulfonyl group An amino group (1-5 carbon atoms), an allylsulfonylamino group which may be substituted, or a sulfonic acid group;
R ³ is a monocyclic or bicyclic aromatic ring which may have a substituent, a monocyclic or bicyclic heterocycle which may have a substituent, or a cyclo which may have a substituent. Showing the ring,
R ⁴ represents a monocyclic or bicyclic aromatic ring which may have a substituent, or a monocyclic or bicyclic heterocyclic ring which may have a substituent,
X is —CH ₂ —, a carbon atom having an optionally branched lower alkyl group, an oxygen atom, a carbonyl group, a carbon atom having a ring containing an oxygen atom, a sulfur atom, —SO ₂ —, or a substituent. A nitrogen atom which may have a group,
Y is —CH ₂ CH ₂ — (CH ₂ ) _m —, —CR ⁵ ═CR ⁶ — (CH ₂ ) _m — (R ⁵ and R ⁶ may be the same or different, and may be a hydrogen atom, a halogen atom, Lower alkyl group), —O—CH ₂ — (CH ₂ ) _m —, (optionally substituted cyclocycle (1-5 carbon atoms)) — (CH ₂ ) _m —, ethynylene group, or (which may have a substituent monocyclic or bicyclic aromatic _{ring) -} (CH 2) m - indicates,
m is 0-5,
Z represents a bond, —C (═O) —, —C (═S) —, or —SO ₂ —;
n represents 0 to 5;
Note that each lower alkyl group has 1 to 5 carbon atoms]
Or a pharmaceutically acceptable salt, hydrate or solvate thereof. General formula (II):

[ Wherein R ¹ and R ² are a hydrogen atom, a monocyclic or bicyclic aromatic ring optionally having a substituent, a monocyclic or bicyclic heterocyclic ring optionally having a substituent, branched A lower alkyl group which may form a ring, a lower alkyl group to which a monocyclic or bicyclic aromatic ring or heterocyclic ring which may have a substituent is bonded, a lower alkoxy group A lower alkyl group having an allyloxy group which may have a substituent, a lower alkyl group having a lower haloalkyloxy group, a lower alkyl group having an amino group which may have a substituent, lower alkylthio Group having lower alkyl group, lower alkyl group having lower alkylsulfonyl group, lower alkyl group having carboxyl group, lower alkyl group having lower alkoxycarbonyl group, lower alkyl group having sulfonamide group Kill group, lower alkyl group having hydroxyl group, lower alkyl group having sulfonic acid, lower alkyl group having cyano group, lower alkyl group having nitro group, lower haloalkyl group, lower alkoxy group (1-5 carbon atoms), lower Haloalkoxy group (1-5 carbon atoms), lower alkoxycarbonyl group (1-5 carbon atoms), halogen atom, hydroxyl group, cyano group, carboxyl group, nitro group, amino group which may be substituted, carbamoyl group, aminosulfonyl Group, lower alkanoyl group (1-5 carbon atoms), optionally substituted allylcarbonyl group, lower alkoxycarbonyl group (1-5 carbon atoms), lower alkylthio group (1-5 carbon atoms), optionally substituted. Allylthio group, lower alkylsulfonyl group (1-5 carbon atoms), optionally substituted allylsulfonyl group, lower alkylsulfonyl group Amino group (1-5 carbon atoms), which may be substituted allyl sulfonylamino group, or represents a sulfonic acid group,
R ³ is a monocyclic or bicyclic aromatic ring which may have a substituent, a monocyclic or bicyclic heterocycle which may have a substituent, or a cyclo which may have a substituent. Showing the ring,
R ⁴ represents a monocyclic or bicyclic aromatic ring which may have a substituent, or a monocyclic or bicyclic heterocyclic ring which may have a substituent,
X is —CH ₂ —, a carbon atom having a lower alkyl group that may be branched, an oxygen atom, a carbonyl group, a carbon atom having a ring containing an oxygen atom, a sulfur atom, —SO ₂ —, or A nitrogen atom which may have a substituent,
Z represents a bond, —C (═O) —, —C (═S) —, or —SO ₂ —;
n represents 0-5, m represents 0-5, and the carbon number of each lower alkyl group is 1-5 ]
Or a pharmaceutically acceptable salt, hydrate or solvate thereof. General formula (III):

[ Wherein , R ¹ and R ² are a hydrogen atom, a monocyclic or bicyclic aromatic ring optionally having a substituent, a monocyclic or bicyclic heterocyclic ring optionally having a substituent, Lower alkyl group which may be branched, alkyl group which may form a ring, lower alkyl group which monocyclic or bicyclic aromatic ring or heterocyclic ring which may have a substituent is bonded, lower alkoxy A lower alkyl group having a group, a lower alkyl group having an allyloxy group which may have a substituent, a lower alkyl group having a lower haloalkyloxy group, a lower alkyl group having an amino group which may have a substituent, Lower alkyl group having alkylthio group, lower alkyl group having lower alkylsulfonyl group, lower alkyl group having carboxyl group, lower alkyl group having lower alkoxycarbonyl group, lower group having sulfonamide group Alkyl group, lower alkyl group having hydroxyl group, lower alkyl group having sulfonic acid, lower alkyl group having cyano group, lower alkyl group having nitro group, lower haloalkyl group, lower alkoxy group (1-5 carbon atoms), lower Haloalkoxy group (1-5 carbon atoms), lower alkoxycarbonyl group (1-5 carbon atoms), halogen atom, hydroxyl group, cyano group, carboxyl group, nitro group, amino group which may be substituted, carbamoyl group, aminosulfonyl Group, lower alkanoyl group (1-5 carbon atoms), optionally substituted allylcarbonyl group, lower alkoxycarbonyl group (1-5 carbon atoms), lower alkylthio group (1-5 carbon atoms), optionally substituted. Allylthio group, lower alkylsulfonyl group (1-5 carbon atoms), optionally substituted allylsulfonyl group, lower alkylsulfo group Arylamino group (1-5 carbon atoms), which may be substituted allyl sulfonylamino group, or represents a sulfonic acid group,
R ³ may have a monocyclic or bicyclic aromatic ring which may have a substituent, a monocyclic or bicyclic heterocyclic ring which may have a substituent, or a substituent. Represents a cyclo ring,
R ⁴ represents a monocyclic or bicyclic aromatic ring which may have a substituent, or a monocyclic or bicyclic heterocyclic ring which may have a substituent,
X is —CH ₂ —, a carbon atom having a lower alkyl group that may be branched, an oxygen atom, a carbonyl group, a carbon atom having a ring containing an oxygen atom, a sulfur atom, —SO ₂ —, or A nitrogen atom which may have a substituent,
Z represents a bond, —C (═O) —, —C (═S) —, or —SO ₂ —, n represents 0 to 5, m represents 0 to 5; The carbon number of the group is 1-5 ]
Or a pharmaceutically acceptable salt, hydrate or solvate thereof. Formula (IV):

[ Wherein , R ¹ and R ² are a hydrogen atom, a monocyclic or bicyclic aromatic ring optionally having a substituent, a monocyclic or bicyclic heterocyclic ring optionally having a substituent, Lower alkyl group which may be branched, alkyl group which may form a ring, lower alkyl group which monocyclic or bicyclic aromatic ring or heterocyclic ring which may have a substituent is bonded, lower alkoxy A lower alkyl group having a group, a lower alkyl group having an allyloxy group which may have a substituent, a lower alkyl group having a lower haloalkyloxy group, a lower alkyl group having an amino group which may have a substituent, Lower alkyl group having alkylthio group, lower alkyl group having lower alkylsulfonyl group, lower alkyl group having carboxyl group, lower alkyl group having lower alkoxycarbonyl group, lower group having sulfonamide group Alkyl group, lower alkyl group having hydroxyl group, lower alkyl group having sulfonic acid, lower alkyl group having cyano group, lower alkyl group having nitro group, lower haloalkyl group, lower alkoxy group (1-5 carbon atoms), lower Haloalkoxy group (1-5 carbon atoms), lower alkoxycarbonyl group (1-5 carbon atoms), halogen atom, hydroxyl group, cyano group, carboxyl group, nitro group, amino group which may be substituted, carbamoyl group, aminosulfonyl Group, lower alkanoyl group (1-5 carbon atoms), optionally substituted allylcarbonyl group, lower alkoxycarbonyl group (1-5 carbon atoms), lower alkylthio group (1-5 carbon atoms), optionally substituted. Allylthio group, lower alkylsulfonyl group (1-5 carbon atoms), optionally substituted allylsulfonyl group, lower alkylsulfo group Arylamino group (1-5 carbon atoms), which may be substituted allyl sulfonylamino group, or represents a sulfonic acid group,
R ³ may have a monocyclic or bicyclic aromatic ring which may have a substituent, a monocyclic or bicyclic heterocyclic ring which may have a substituent, or a substituent. Represents a cyclo ring,
R ⁴ represents a monocyclic or bicyclic aromatic ring which may have a substituent, or a monocyclic or bicyclic heterocyclic ring which may have a substituent,
X is —CH ₂ —, a carbon atom having a lower alkyl group that may be branched, an oxygen atom, a carbonyl group, a carbon atom having a ring containing an oxygen atom, a sulfur atom, —SO ₂ —, or A nitrogen atom which may have a substituent,
Z represents a bond, —C (═O) —, —C (═S) —, or —SO ₂ —;
n represents 0-5, m represents 0-5, and the carbon number of each lower alkyl group is 1-5 ]
Or a pharmaceutically acceptable salt, hydrate or solvate thereof. Formula (V):

[ Wherein , R ¹ and R ² are a hydrogen atom, a monocyclic or bicyclic aromatic ring optionally having a substituent, a monocyclic or bicyclic heterocyclic ring optionally having a substituent, Lower alkyl group which may be branched, alkyl group which may form a ring, lower alkyl group which monocyclic or bicyclic aromatic ring or heterocyclic ring which may have a substituent is bonded, lower alkoxy A lower alkyl group having a group, a lower alkyl group having an allyloxy group which may have a substituent, a lower alkyl group having a lower haloalkyloxy group, a lower alkyl group having an amino group which may have a substituent, Lower alkyl group having alkylthio group, lower alkyl group having lower alkylsulfonyl group, lower alkyl group having carboxyl group, lower alkyl group having lower alkoxycarbonyl group, lower group having sulfonamide group Alkyl group, lower alkyl group having hydroxyl group, lower alkyl group having sulfonic acid, lower alkyl group having cyano group, lower alkyl group having nitro group, lower haloalkyl group, lower alkoxy group (1-5 carbon atoms), lower Haloalkoxy group (1-5 carbon atoms), lower alkoxycarbonyl group (1-5 carbon atoms), halogen atom, hydroxyl group, cyano group, carboxyl group, nitro group, amino group which may be substituted, carbamoyl group, aminosulfonyl Group, lower alkanoyl group (1-5 carbon atoms), optionally substituted allylcarbonyl group, lower alkoxycarbonyl group (1-5 carbon atoms), lower alkylthio group (1-5 carbon atoms), optionally substituted. Allylthio group, lower alkylsulfonyl group (1-5 carbon atoms), optionally substituted allylsulfonyl group, lower alkylsulfo group Arylamino group (1-5 carbon atoms), which may be substituted allyl sulfonylamino group, or represents a sulfonic acid group,
R ³ may have a monocyclic or bicyclic aromatic ring which may have a substituent, a monocyclic or bicyclic heterocyclic ring which may have a substituent, or a substituent. Represents a cyclo ring,
R ⁴ represents a monocyclic or bicyclic aromatic ring which may have a substituent, or a monocyclic or bicyclic heterocyclic ring which may have a substituent,
X is —CH ₂ —, a carbon atom having a lower alkyl group that may be branched, an oxygen atom, a carbonyl group, a carbon atom having a ring containing an oxygen atom, a sulfur atom, —SO ₂ —, or A nitrogen atom which may have a substituent,
Z represents a bond, —C (═O) —, —C (═S) —, or —SO ₂ —;
n represents 0-5, m represents 0-5, and the carbon number of each lower alkyl group is 1-5 ]
Or a pharmaceutically acceptable salt, hydrate or solvate thereof. The compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof, wherein X in the general formula (I) is —CH ₂ — or an oxygen atom. The compound according to claim 2, a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein X in the general formula (II) is —CH ₂ — or an oxygen atom. The compound according to claim 3, a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein X in the general formula (III) is —CH ₂ — or an oxygen atom. The compound according to claim 4, a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein X in the general formula (IV) is —CH ₂ — or an oxygen atom. The compound according to claim 5, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein X in the general formula (V) is —CH ₂ — or an oxygen atom.   A pharmaceutical composition for use in the treatment or prevention of a prostaglandin-mediated disease or disease, comprising the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient.   12. The pharmaceutical composition of claim 11, wherein the prostaglandin mediated disease or condition is pain, inflammation, atherosclerosis, myocardial infarction, stroke or vascular occlusive disorder.   A pharmaceutical composition comprising the pharmaceutical composition according to claim 11 or 12, wherein a pharmaceutical agent selected from a platelet aggregation inhibitor, an HMG-CoA reductase inhibitor, an antihyperlipidemic agent and a cyclooxygenase inhibitor is blended.